[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 3192
1. Nguewa PA, Calvo A: Use of transgenic mice as models for prostate cancer chemoprevention. Curr Mol Med; 2010 Nov;10(8):705-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of transgenic mice as models for prostate cancer chemoprevention.
  • Prostate cancer is a long latency type of tumor that usually develops in men older than 50 years of age.
  • Prostate epithelial neoplasia (PIN), the initial malignant lesion, progresses to invasive carcinoma over the course of years.
  • Because of the particular features of prostate carcinogenesis, this type of tumor may represent a paradigm for cancer prevention.
  • Several clinical trials have evaluated the effect of different compounds on prostate tumor development, including finasteride, selenium, vitamin E, and carotenes.
  • However, many novel chemopreventive agents that target different cancer-related pathways are being developed lately.
  • The transgenic adenocarcinoma of the mouse prostate (TRAMP) model has been validated as an accurate model to test a variety of preventive agents.
  • Genistein, alpha-difluoromethylornithine, toremifene, R-flurbiprofen, celecoxib, and green tea polyphenols have been shown to prevent prostate cancer development in TRAMP mice.
  • In conclusion, new chemopreventive compounds which are effective in animal models are likely to be tested soon in clinical trials, with the final goal of reducing prostate cancer incidence in men.
  • [MeSH-major] Anticarcinogenic Agents / therapeutic use. Prostatic Neoplasms / prevention & control
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / genetics. Adenocarcinoma / prevention & control. Animals. Antineoplastic Agents / therapeutic use. Male. Mice. Mice, Transgenic. Models, Animal. Prostate / pathology. Selenium / therapeutic use. Vitamin E / therapeutic use

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. SELENIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20937024.001).
  • [ISSN] 1875-5666
  • [Journal-full-title] Current molecular medicine
  • [ISO-abbreviation] Curr. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Antineoplastic Agents; 1406-18-4 / Vitamin E; H6241UJ22B / Selenium
  •  go-up   go-down


2. Cardillo MR, Ippoliti F: IL-6, IL-10 and HSP-90 expression in tissue microarrays from human prostate cancer assessed by computer-assisted image analysis. Anticancer Res; 2006 Sep-Oct;26(5A):3409-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IL-6, IL-10 and HSP-90 expression in tissue microarrays from human prostate cancer assessed by computer-assisted image analysis.
  • To define the role of IL-6, IL-10 and HSP-90 in prostate cancer progression the immunohistochemical expressions of these proteins were analyzed in 168 prostatic carcinomas.
  • IL-6, IL-10 and HSP-90 immunoreactivity was higher in prostatic carcinoma (CaP) and intra-epithelial prostatic neoplasia (PIN) than in normal prostatic tissue (NAP) adjacent to neoplasia.
  • Our results indicate that the IL-6 and IL-10 cytokine balance differs in pathological and normal prostate, thus suggesting that certain cytokines are specific to the neoplastic prostate.
  • Changes in the expressions of IL-6, IL-10 and HSP-90 in human prostate carcinoma samples could be used as a prognostic marker of disease progression.
  • [MeSH-major] HSP90 Heat-Shock Proteins / metabolism. Interleukin-10 / metabolism. Interleukin-6 / metabolism. Prostatic Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Aged. Aged, 80 and over. Disease Progression. Humans. Image Processing, Computer-Assisted. Male. Middle Aged. Neoplasm Staging. Prostate / metabolism. Prostate / pathology. Prostatectomy. Prostatic Hyperplasia / metabolism. Prostatic Hyperplasia / pathology. Prostatic Hyperplasia / surgery. Prostatic Intraepithelial Neoplasia / metabolism. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Intraepithelial Neoplasia / surgery. Tissue Array Analysis


3. Shrestha BM, Prasopshanti K, Matanhelia SS, Peeling WB: Blood loss during and after transurethral resection of prostate: a prospective study. Kathmandu Univ Med J (KUMJ); 2008 Jul-Sep;6(23):329-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blood loss during and after transurethral resection of prostate: a prospective study.
  • OBJECTIVES: Transurethral resection of prostate (TURP) is the gold standard treatment for symptomatic prostatic bladder outlet obstruction.
  • The purpose of this study was to assess the influence of anaesthesia, operating time, weight of resected prostatic tissue and its histology on blood loss during and after TURP and to revisit the available body of evidence in the literature of urology.
  • MATERIALS AND METHODS: This is a prospective study of a cohort of 100 consecutive patients who had undergone TURP over a period of one year, where the data was collected on a performa specifically designed for the study, which included the type of anaesthesia administered, resection time, amount of blood lost during and after TURP, weight of the resected prostatic tissue and histology.
  • The total operating time (SA: 29.70 (10-55); GA: 29.80 (10-65) minutes) and weight of resected prostate (SA: 21.90 (3-45); GA: 18.00 (4-60) gms) were similar between the two groups.
  • CONCLUSIONS: The intraoperative, postoperative and total blood losses related to TURP were not influenced by the type of anaesthesia, resection time, weight of the resected prostate and the histology.
  • [MeSH-major] Blood Loss, Surgical / statistics & numerical data. Postoperative Hemorrhage / etiology. Prostate / surgery. Transurethral Resection of Prostate / adverse effects
  • [MeSH-minor] Adenocarcinoma / surgery. Aged. Aged, 80 and over. Aspirin / therapeutic use. Blood Volume. Cohort Studies. Humans. Male. Middle Aged. Platelet Aggregation Inhibitors / therapeutic use. Prospective Studies. Prostatic Hyperplasia / surgery. Prostatic Neoplasms / surgery. Prostatitis / surgery. Urinary Catheterization. Urinary Tract Infections / complications

  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20071814.001).
  • [ISSN] 1812-2078
  • [Journal-full-title] Kathmandu University medical journal (KUMJ)
  • [ISO-abbreviation] Kathmandu Univ Med J (KUMJ)
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Nepal
  • [Chemical-registry-number] 0 / Platelet Aggregation Inhibitors; R16CO5Y76E / Aspirin
  •  go-up   go-down


Advertisement
4. Wartenberg M, Richter M, Datchev A, Günther S, Milosevic N, Bekhite MM, Figulla HR, Aran JM, Pétriz J, Sauer H: Glycolytic pyruvate regulates P-Glycoprotein expression in multicellular tumor spheroids via modulation of the intracellular redox state. J Cell Biochem; 2010 Feb 1;109(2):434-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To investigate the effect of glycolysis and the tissue redox state on P-gp expression in multicellular tumor spheroids derived from prostate adenocarcinoma cells (DU-145), glioma cells (Gli36), and the human cervix carcinoma cell line KB-3-1 transfected with a P-gp-EGFP fusion gene that allows monitoring of P-gp expression in living cells.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Antibiotics, Antineoplastic / pharmacokinetics. Cell Line, Tumor. Doxorubicin / pharmacokinetics. Drug Resistance, Multiple / drug effects. Drug Resistance, Neoplasm. Glycolysis. Humans. Lactic Acid / metabolism. Male. Oxidation-Reduction. Prostatic Neoplasms / metabolism. Prostatic Neoplasms / pathology

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. LACTIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19950199.001).
  • [ISSN] 1097-4644
  • [Journal-full-title] Journal of cellular biochemistry
  • [ISO-abbreviation] J. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / P-Glycoprotein; 0 / Reactive Oxygen Species; 33X04XA5AT / Lactic Acid; 80168379AG / Doxorubicin; 8558G7RUTR / Pyruvic Acid
  •  go-up   go-down


5. Kniaz'kin IV: [Melatonin, aging and tumors of the prostate]. Adv Gerontol; 2008;21(1):74-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Melatonin, aging and tumors of the prostate].
  • Morphological changes that take place in the epiphysis in the course of age involution are inseparably associated with a drastic decrease in the synthesis of melatonin (MT) - the main hormone of the pineal gland that coordinates biorhythms of the body at all system levels.
  • The pineal gland is not the only organ able producing MT Multiple research have proved that the extrapineal MT is also widely present in human and animal organism.
  • In this paper we present the results of our own research upon whose analysis we can base a hypothesis that MT and serotonin can play an important role in the mechanisms of the prostate aging.
  • On the one hand, they both can perform regulatory function for the prostate's normal work; on the other, these agents in one form or another can take part in the pathogenesis of such disfunctions as cancer and benign prostate hyperplasia.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • Hazardous Substances Data Bank. MELATONIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18546827.001).
  • [ISSN] 1561-9125
  • [Journal-full-title] Advances in gerontology = Uspekhi gerontologii
  • [ISO-abbreviation] Adv Gerontol
  • [Language] RUS
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 333DO1RDJY / Serotonin; JL5DK93RCL / Melatonin
  •  go-up   go-down


6. Leav I, Plescia J, Goel HL, Li J, Jiang Z, Cohen RJ, Languino LR, Altieri DC: Cytoprotective mitochondrial chaperone TRAP-1 as a novel molecular target in localized and metastatic prostate cancer. Am J Pathol; 2010 Jan;176(1):393-401
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoprotective mitochondrial chaperone TRAP-1 as a novel molecular target in localized and metastatic prostate cancer.
  • Here, we show that a mitochondria-localized Hsp90 chaperone, tumor necrosis factor receptor-associated protein-1 (TRAP-1), is abundantly and ubiquitously expressed in human high-grade prostatic intraepithelial neoplasia, Gleason grades 3 through 5 prostatic adenocarcinomas, and metastatic prostate cancer, but largely undetectable in normal prostate or benign prostatic hyperplasia in vivo.
  • Prostate lesions formed in genetic models of the disease, including the transgenic adenocarcinoma of the mouse prostate and mice carrying prostate-specific deletion of the phosphatase tensin homolog tumor suppressor (Pten(pc-/-)), also exhibit high levels of TRAP-1.
  • Expression of TRAP-1 in nontransformed prostatic epithelial BPH-1 cells inhibited cell death, whereas silencing of TRAP-1 in androgen-independent PC3 or DU145 prostate cancer cells by small interfering RNA enhanced apoptosis.
  • Targeting TRAP-1 with a novel class of mitochondria-directed Hsp90 inhibitors, ie, Gamitrinibs, caused rapid and complete killing of androgen-dependent or -independent prostate cancer, but not BPH-1 cells, whereas reintroduction of TRAP-1 in BPH-1 cells conferred sensitivity to Gamitrinib-induced cell death.
  • These data identify TRAP-1 as a novel mitochondrial survival factor differentially expressed in localized and metastatic prostate cancer compared with normal prostate.
  • Targeting this pathway with Gamitrinibs could be explored as novel molecular therapy in patients with advanced prostate cancer.

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):584-93 [12154351.001]
  • [Cites] Science. 2001 Apr 27;292(5517):727-30 [11326099.001]
  • [Cites] Prostate. 2003 May 15;55(3):219-37 [12692788.001]
  • [Cites] Nature. 2003 Sep 25;425(6956):407-10 [14508491.001]
  • [Cites] Cancer Cell. 2003 Sep;4(3):209-21 [14522255.001]
  • [Cites] Nat Med. 2004 Jun;10(6):594-601 [15156201.001]
  • [Cites] Science. 2004 Jul 30;305(5684):626-9 [15286356.001]
  • [Cites] N Engl J Med. 2004 Oct 7;351(15):1488-90 [15470210.001]
  • [Cites] N Engl J Med. 2004 Oct 7;351(15):1513-20 [15470214.001]
  • [Cites] Cancer Res. 1994 May 15;54(10):2577-81 [8168083.001]
  • [Cites] Nature. 2005 Mar 31;434(7033):652-8 [15800626.001]
  • [Cites] Nature. 2005 Mar 31;434(7033):658-62 [15800627.001]
  • [Cites] Nat Rev Cancer. 2005 Oct;5(10):761-72 [16175177.001]
  • [Cites] Oncology. 2005;69(4):273-82 [16282706.001]
  • [Cites] J Natl Cancer Inst. 2006 Nov 1;98(21):1521-7 [17077354.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):256-69 [17384581.001]
  • [Cites] Arch Pathol Lab Med. 2007 Jul;131(7):1103-9 [17616999.001]
  • [Cites] J Biol Chem. 2007 Jul 13;282(28):20553-60 [17513296.001]
  • [Cites] J Clin Invest. 2007 Sep;117(9):2351-61 [17786228.001]
  • [Cites] J Urol. 2007 Nov;178(5):1846-54 [17868738.001]
  • [Cites] Cell. 2007 Oct 19;131(2):257-70 [17956728.001]
  • [Cites] Stress. 2007 Nov;10(4):342-50 [17853063.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] FASEB J. 2008 Sep;22(9):3264-75 [18524868.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20882-7 [19088204.001]
  • [Cites] J Clin Invest. 2009 Mar;119(3):454-64 [19229106.001]
  • [Cites] Mol Cell. 2009 Mar 13;33(5):627-38 [19285945.001]
  • [Cites] PLoS Biol. 2007 Jul;5(7):e172 [17579517.001]
  • [Cites] FEBS Lett. 2002 Feb 13;512(1-3):1-7 [11852041.001]
  • [Cites] J Biol Chem. 2000 Feb 4;275(5):3305-12 [10652318.001]
  • [Cites] Cancer Cell. 2003 Mar;3(3):213-7 [12676580.001]
  • (PMID = 19948822.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA078810; United States / NCI NIH HHS / CA / R01 CA089720; United States / NCI NIH HHS / CA / CA118005; United States / NCI NIH HHS / CA / R01 CA109874-05; United States / NCI NIH HHS / CA / CA78810; United States / NCI NIH HHS / CA / CA109874-05; United States / NCI NIH HHS / CA / R01 CA109874; United States / NCI NIH HHS / CA / R01 CA089720-05; United States / NCI NIH HHS / CA / CA90917; United States / NCI NIH HHS / CA / CA089720-05; United States / NCI NIH HHS / CA / CA109874; United States / NCI NIH HHS / CA / CA89720; United States / NCI NIH HHS / CA / R56 CA089720; United States / NCI NIH HHS / CA / R01 CA118005; United States / NCI NIH HHS / CA / R01 CA090917
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HSP90 Heat-Shock Proteins; 0 / Molecular Chaperones; 0 / TRAP-1 protein, mouse; 0 / TRAP1 protein, human
  • [Other-IDs] NLM/ PMC2797899
  •  go-up   go-down


7. Choe KS, Jani AB, Liauw SL: External beam radiotherapy for prostate cancer patients on anticoagulation therapy: how significant is the bleeding toxicity? Int J Radiat Oncol Biol Phys; 2010 Mar 1;76(3):755-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] External beam radiotherapy for prostate cancer patients on anticoagulation therapy: how significant is the bleeding toxicity?
  • PURPOSE: To characterize the bleeding toxicity associated with external beam radiotherapy for prostate cancer patients receiving anticoagulation (AC) therapy.
  • METHODS AND MATERIALS: The study cohort consisted of 568 patients with adenocarcinoma of the prostate who were treated with definitive external beam radiotherapy.
  • Multivariate analysis within the AC group demonstrated that a higher radiotherapy dose (p = .0408), intensity-modulated radiotherapy (p = 0.0136), and previous transurethral resection of the prostate (p = .0001) were associated with Grade 2 or worse bleeding toxicity.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Anticoagulants / adverse effects. Hemorrhage / etiology. Prostatic Neoplasms / radiotherapy. Radiotherapy, Conformal / adverse effects
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Androgen Antagonists / therapeutic use. Follow-Up Studies. Humans. Male. Middle Aged. Multivariate Analysis. Radiotherapy Dosage. Radiotherapy, Intensity-Modulated / adverse effects. Rectum / radiation effects. Severity of Illness Index. Ticlopidine / adverse effects. Ticlopidine / analogs & derivatives. Transurethral Resection of Prostate / adverse effects. Urologic Diseases / etiology. Warfarin / adverse effects

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Bleeding.
  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CLOPIDOGREL .
  • Hazardous Substances Data Bank. WARFARIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19464123.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Anticoagulants; 5Q7ZVV76EI / Warfarin; A74586SNO7 / clopidogrel; OM90ZUW7M1 / Ticlopidine
  •  go-up   go-down


8. Gotto GT, Cronin AM, Laudone VP: Important considerations in the clinical use of preoperative prostate cancer predictive nomograms. Eur Urol; 2010 Oct;58(4):637-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Important considerations in the clinical use of preoperative prostate cancer predictive nomograms.
  • [MeSH-major] Adenocarcinoma / surgery. Nomograms. Preoperative Care. Prostatic Neoplasms / surgery

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20705389.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] Switzerland
  •  go-up   go-down


9. Kim SH, Chao ST, Toms SA, Vogelbaum MA, Barnett GH, Suh JH, Weil RJ: Stereotactic radiosurgical treatment of parenchymal brain metastases from prostate adenocarcinoma. Surg Neurol; 2008 Jun;69(6):641-6; discussion 646
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic radiosurgical treatment of parenchymal brain metastases from prostate adenocarcinoma.
  • BACKGROUND: Prostate cancer metastatic to the brain is uncommon and has been associated historically with a poor prognosis.
  • METHODS: We analyzed a prospective, institutional review board-approved database of patients treated with SRS and identified 5 patients with prostate cancer metastasis.
  • Two patients died of conditions unrelated to prostate cancer and 2 of systemic disease progression; 1is alive and asymptomatic.
  • CONCLUSIONS: Stereotactic radiosurgery for prostate cancer metastatic to the brain, alone or in combination with brain radiation therapy and surgery, is a safe, effective treatment that improves neurologic symptoms and function and may prolong survival.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Brain Neoplasms / secondary. Brain Neoplasms / surgery. Prostatic Neoplasms / pathology. Radiosurgery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18262258.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


10. Sternberg CN: Satraplatin in the treatment of hormone-refractory prostate cancer. BJU Int; 2005 Nov;96(7):990-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Satraplatin in the treatment of hormone-refractory prostate cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Organoplatinum Compounds / administration & dosage. Prostatic Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] BJU Int. 2006 Jan;97(1):211
  • (PMID = 16225514.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 8D7B37T28G / satraplatin; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


11. Goel T, Garg S: Role of AgNOR count and its correlation with serum PSA levels in prostatic lesions. Urol Int; 2009;82(3):286-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of AgNOR count and its correlation with serum PSA levels in prostatic lesions.
  • OBJECTIVE: Prostatic diseases are a major cause of morbidity and mortality.
  • Prostate-specific antigen (PSA) is not very sensitive, thus other indices are being employed.
  • Our main objective was to evaluate the role of AgNOR in prostatic lesions and to find a correlation between serum PSA and AgNOR counts.
  • PATIENTS AND METHODS: We evaluated 60 patients of prostate diseases over a year.
  • The patients were classified as benign prostatic hyperplasia (BPH), prostatitis, or prostatic adenocarcinoma (Ca).
  • Patients with suspicious areas or foci of prostatic intraepithelial neoplasia (PIN) on histology were subjected to a slide review.
  • The difference between low- and high-grade PIN was also significant.Ca prostate showed a significant increase in AgNOR counts from benign diseases; and also between localized and metastatic carcinoma (p < 0.001).
  • CONCLUSIONS: Our study depicts the usefulness of AgNOR counts in the diagnosis of various prostatic diseases including the pre malignant PIN.
  • The relation between serum PSA and AgNOR was highly significant for BPH and Ca prostate.
  • [MeSH-major] Adenocarcinoma / diagnosis. Antigens, Nuclear / analysis. Prostate-Specific Antigen / blood. Prostatic Hyperplasia / diagnosis. Prostatic Intraepithelial Neoplasia / diagnosis. Prostatic Neoplasms / diagnosis. Prostatitis / diagnosis


12. Madabhushi A, Feldman MD, Metaxas DN, Tomaszeweski J, Chute D: Automated detection of prostatic adenocarcinoma from high-resolution ex vivo MRI. IEEE Trans Med Imaging; 2005 Dec;24(12):1611-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Automated detection of prostatic adenocarcinoma from high-resolution ex vivo MRI.
  • Prostatic adenocarcinoma is the most commonly occurring cancer among men in the United States, second only to skin cancer.
  • Currently, the only definitive method to ascertain the presence of prostatic cancer is by trans-rectal ultrasound (TRUS) directed biopsy.
  • High-resolution magnetic resonance imaging (MRI) has been shown to have a higher accuracy of prostate cancer detection compared to ultrasound.
  • Consequently, several researchers have been exploring the use of high resolution MRI in performing prostate biopsies.
  • Visual detection of prostate cancer, however, continues to be difficult owing to its apparent lack of shape, and the fact that several malignant and benign structures have overlapping intensity and texture characteristics.
  • In this paper, we present a fully automated computer-aided detection (CAD) system for detecting prostatic adenocarcinoma from 4 Tesla ex vivo magnetic resonance (MR) imagery of the prostate.
  • We evaluated our CAD system on a total of 33 two-dimensional (2-D) MR slices from five different 3-D MR prostate studies.
  • Future work will focus on extending the methodology to guide high-resolution MRI-assisted in vivo prostate biopsies.
  • [MeSH-major] Adenocarcinoma / pathology. Image Enhancement / methods. Image Interpretation, Computer-Assisted / methods. Imaging, Three-Dimensional / methods. Magnetic Resonance Imaging / methods. Pattern Recognition, Automated / methods. Prostatic Neoplasms / pathology


13. Tang JI, Williams SG, Tai KH, Dean J, Duchesne GM: A prospective dose escalation trial of high-dose-rate brachytherapy boost for prostate cancer: Evidence of hypofractionation efficacy? Brachytherapy; 2006 Oct-Dec;5(4):256-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective dose escalation trial of high-dose-rate brachytherapy boost for prostate cancer: Evidence of hypofractionation efficacy?
  • METHODS AND MATERIALS: We analyzed data from 88 patients with T1a-T3a, N0, M0 prostate adenocarcinoma treated on a prospective Phase I/II HDRB boost protocol of 16 (n = 47) or 20 Gy (n = 41) in four fractions, without planned androgen deprivation therapy.
  • The primary endpoint was freedom from biochemical failure, defined as a 2 ng/mL rise above the lowest prostate-specific antigen (PSA) (FFbFn2), whereas the American Society of Therapeutic Radiology and Oncology consensus definition (ACD) was used for comparative purposes.
  • CONCLUSIONS: The data support HDRB boost as a potential means of dose escalation in prostate cancer.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy / methods. Prostatic Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Aged, 80 and over. Humans. Male. Middle Aged. Prostate-Specific Antigen / blood. Radiotherapy Dosage. Retrospective Studies

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17118320.001).
  • [ISSN] 1538-4721
  • [Journal-full-title] Brachytherapy
  • [ISO-abbreviation] Brachytherapy
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


14. Gatti G, Quintar AA, Andreani V, Nicola JP, Maldonado CA, Masini-Repiso AM, Rivero VE, Maccioni M: Expression of Toll-like receptor 4 in the prostate gland and its association with the severity of prostate cancer. Prostate; 2009 Sep 15;69(13):1387-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Toll-like receptor 4 in the prostate gland and its association with the severity of prostate cancer.
  • BACKGROUND: Chronic inflammation has been postulated to be an important driving force to prostate carcinoma.
  • Recently, functional TLRs have been shown to be also expressed in numerous cancer cells, but their significance has only recently begun to be explored.
  • The purpose of this study was to investigate the putative role of TLR4 expression in prostate carcinoma.
  • METHODS: To determine if there is an association between TLR4 expression and the malignancy of the tumor, 35 prostate carcinoma samples showing different Gleason grades were analyzed by immunohistochemistry.
  • Also, to explore the functionality of the receptors expressed on the epithelium, we analyzed the type of cytokine response elicited and the signaling pathways involved after TLR4 triggering in the human prostate adenocarcinoma cell line, DU-145.
  • RESULTS: TLR4 is expressed in the normal prostate gland in both stroma and epithelium.
  • CONCLUSIONS: We hypothesize that TLR4 in prostate cells could synergize with innate immune cells contributing to an eventual inflammatory process, which in genetically prone individuals could promote carcinogenesis.
  • Prostate 69: 1387-1397, 2009. (c) 2009 Wiley-Liss, Inc.
  • [MeSH-major] Adenocarcinoma / immunology. Prostate / physiology. Prostatic Neoplasms / immunology. Prostatitis / immunology. Toll-Like Receptor 4 / genetics. Toll-Like Receptor 4 / metabolism

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19496069.001).
  • [ISSN] 1097-0045
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chemokines; 0 / Cytokines; 0 / TLR4 protein, human; 0 / Toll-Like Receptor 4
  •  go-up   go-down


15. Urbanskiĭ AI: [Correlation between size and localization of stage-pT adenocarcinoma of the prostate]. Vopr Onkol; 2006;52(6):649-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlation between size and localization of stage-pT adenocarcinoma of the prostate].
  • According to the data on resected material sampled from 58 cases of radical prostatectomy, a relationship between size of adenocarcinoma and prostate and localization of the main tumor node, on the one hand, and pathological stage (pT) of primary tumor was established.
  • Incidence of pT3 was dependent on tumor volume when adenocarcinoma was in the periphery of the prostate which involved the following relationships between pT, on the one hand, and tumor size and site, on the other: the closer tumor to the gland center, the lower the value of pT.
  • Risk of pT3 appeared to be associated with small size of the prostate.
  • [MeSH-major] Adenocarcinoma / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17338242.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


16. Cho-Vega JH, Tsavachidis S, Do KA, Nakagawa J, Medeiros LJ, McDonnell TJ: Dicarbonyl/L-xylulose reductase: a potential biomarker identified by laser-capture microdissection-micro serial analysis of gene expression of human prostate adenocarcinoma. Cancer Epidemiol Biomarkers Prev; 2007 Dec;16(12):2615-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dicarbonyl/L-xylulose reductase: a potential biomarker identified by laser-capture microdissection-micro serial analysis of gene expression of human prostate adenocarcinoma.
  • To identify genes involved in prostate carcinogenesis, we used laser-capture microdissection-micro serial analysis of gene expression to construct libraries of paired cancer and normal cells from human tissue samples.
  • After computational comparison of the two libraries, we identified dicarbonyl/l-xylulose reductase (DCXR), an enzyme that catalyzes alpha-dicarbonyl and l-xylulose, as being significantly up-regulated in prostate cancer cells.
  • The specificity of DCXR up-regulation for prostate cancer tissues was confirmed by quantitative real-time reverse transcriptase-PCR, virtual Northern blot, and Western blot analyses.
  • Furthermore, DCXR expression at the protein level was assessed using fresh-frozen tissues and a tissue microarray consisting of 46 cases of organ-confined early-stage prostate cancer and 29 cases of chemohormonally treated prostate cancer.
  • In most normal prostate epithelial cells, DCXR was expressed at low levels and was localized predominantly in the cytoplasmic membrane.
  • In contrast, in virtually all grades of early-stage prostate cancer and in all chemohormonally treated cases, DCXR was strikingly overexpressed and was localized predominantly in the cytoplasm and nucleus.
  • Based on these findings, we suggest that DCXR overexpression has the potential to be an additional useful biomarker for prostate cancer.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18086765.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / CA-16672
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.1.- / Sugar Alcohol Dehydrogenases; EC 1.1.1.10 / L-xylulose reductase
  •  go-up   go-down


17. Kinebuchi Y, Noguchi W, Irie K, Nakayama T, Kato H, Nishizawa O: Relapsed prostate cancer with neuroendocrine differentiation and high serum levels of carcinoembryonic antigen without elevation of prostrate-specific antigen: a case report. Int J Urol; 2007 Feb;14(2):147-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relapsed prostate cancer with neuroendocrine differentiation and high serum levels of carcinoembryonic antigen without elevation of prostrate-specific antigen: a case report.
  • A 62-year-old man had been treated with combined androgen blockade due to cT2bN1M0 prostate cancer, and his serum prostate-specific antigen (PSA) levels decreased and remained under the level of 0.5 ng/mL during therapy.
  • He underwent transrectal and transurethral biopsy of the prostate, which revealed adenocarcinoma positive for CEA and chromogranin A.
  • [MeSH-major] Adenocarcinoma / blood. Adenocarcinoma / pathology. Carcinoembryonic Antigen / blood. Neoplasm Recurrence, Local / blood. Neoplasm Recurrence, Local / pathology. Prostate-Specific Antigen / blood. Prostatic Neoplasms / blood. Prostatic Neoplasms / pathology


18. Jhavar S, Bartlett J, Kovacs G, Corbishley C, Dearnaley D, Eeles R, Khoo V, Huddart R, Horwich A, Thompson A, Norman A, Brewer D, Cooper CS, Parker C: Biopsy tissue microarray study of Ki-67 expression in untreated, localized prostate cancer managed by active surveillance. Prostate Cancer Prostatic Dis; 2009;12(2):143-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biopsy tissue microarray study of Ki-67 expression in untreated, localized prostate cancer managed by active surveillance.
  • Active surveillance provides a unique opportunity to study biomarkers of prostate cancer behaviour, although only small volumes of tumor tissue are typically available.
  • We have evaluated a technique for constructing tissue microarrays (TMAs) from needle biopsies for assessing immunohistochemical markers in localized prostate cancer managed by active surveillance.
  • TMAs were constructed from diagnostic prostate biopsies for 60 patients with localized prostatic adenocarcinoma in a prospective cohort study of active surveillance.
  • Radical treatment was recommended for a prostate-specific antigen (PSA) velocity greater than 1 ng ml(-1) per year or adverse histology in repeat biopsies, defined as Gleason score > or =4+3 or >50% of cores involved.
  • TMAs constructed from prostate needle biopsies can be used to assess immunohistochemical markers in localized prostate cancer managed by active surveillance.
  • Ki-67 LI merits further study as a possible biomarker of early prostate cancer behaviour.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / analysis. Ki-67 Antigen / biosynthesis. Prostatic Neoplasms / metabolism. Tissue Array Analysis / methods
  • [MeSH-minor] Aged. Biopsy, Needle. Cohort Studies. Disease Progression. Humans. Immunohistochemistry. Male. Membrane Proteins / biosynthesis. Middle Aged. Neoplasm Staging. Prognosis. Prostate-Specific Antigen. Prostatectomy. Racemases and Epimerases / biosynthesis

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18762814.001).
  • [ISSN] 1476-5608
  • [Journal-full-title] Prostate cancer and prostatic diseases
  • [ISO-abbreviation] Prostate Cancer Prostatic Dis.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / 10588; United Kingdom / Medical Research Council / / G0501019; United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Ki-67 Antigen; 0 / Membrane Proteins; EC 3.4.21.77 / Prostate-Specific Antigen; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


19. Friedland JL, Freeman DE, Masterson-McGary ME, Spellberg DM: Stereotactic body radiotherapy: an emerging treatment approach for localized prostate cancer. Technol Cancer Res Treat; 2009 Oct;8(5):387-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic body radiotherapy: an emerging treatment approach for localized prostate cancer.
  • Here we report results from the first cohort of over 100 patients treated with hypofractionated, stereotactic body radiotherapy (SBRT) for early stage prostate cancer.
  • Between February 2005 and December 2006, 112 patients with localized, biopsy-proven adenocarcinoma of the prostate (clinical stage T1cN0M0 to T2cN0M0) were treated in Naples, FL on a CyberKnife system (Accuray Incorporated, Sunnyvale, CA).
  • Mean initial PSA was 6.0, and mean initial prostate volume was 46.3cc.
  • Patients received 35-36 Gy administered in 5 consecutive fractions to the prostate and the proximal seminal vesicles, as identified on CT and MRI scans.
  • [MeSH-major] Adenocarcinoma / surgery. Prostatic Neoplasms / surgery. Radiosurgery
  • [MeSH-minor] Aged. Aged, 80 and over. Cohort Studies. Dose Fractionation. Follow-Up Studies. Humans. Male. Middle Aged. Prostate / metabolism. Prostate / pathology


20. Eisenberg ML, Shinohara K: Partial salvage cryoablation of the prostate for recurrent prostate cancer after radiotherapy failure. Urology; 2008 Dec;72(6):1315-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Partial salvage cryoablation of the prostate for recurrent prostate cancer after radiotherapy failure.
  • OBJECTIVES: To determine the efficacy of partial cryoablation of the prostate in the salvage setting.
  • METHODS: All patients who were treated between April 2004 and September 2007 for recurrent prostate adenocarcinoma after failure of primary radiotherapy by means of partial cryoablation were identified.
  • One of 10 patients harbored residual carcinoma on routine follow-up biopsy at 1 year, whereas 50% harbored residual benign prostate tissue.
  • CONCLUSIONS: In properly selected patients with a unilateral focus of disease recurrence after radiotherapy, acceptable oncologic results can be achieved with partial cryoablation of the prostate, with low morbidity.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adenocarcinoma / therapy. Cryosurgery / methods. Prostatic Neoplasms / pathology. Prostatic Neoplasms / radiotherapy. Prostatic Neoplasms / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy. Humans. Male. Middle Aged. Prostate-Specific Antigen / blood. Recurrence. Retrospective Studies. Salvage Therapy. Treatment Outcome


21. Gelabert A: [Editorial comment on: Outcomes of maximal androgen blockade in prostate cancer patients at a health area with type 2 reference hospital. Part 2. Quality of life: application of EORTC QLQ-PR25 instrument and global results. Quality-of-life adjusted survival. Pharmaceutical expenses and cost-utility]. Arch Esp Urol; 2009 Sep;62(7):571-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Editorial comment on: Outcomes of maximal androgen blockade in prostate cancer patients at a health area with type 2 reference hospital. Part 2. Quality of life: application of EORTC QLQ-PR25 instrument and global results. Quality-of-life adjusted survival. Pharmaceutical expenses and cost-utility].
  • [Transliterated title] Comentario editorial de: Resultados del uso en cancer de próstata del bloqueo androgenico completo en area de salud con hospital de referencia tipo 2 (2 parte). Calidad de vida: aplicacion del instrumento EORTC QLQ-PR25 y resultados globales. Supervivencia ajustada a la calidad de vida. Gasto farmaceutico y coste-utilidad.
  • [MeSH-major] Adenocarcinoma / drug therapy. Androgen Antagonists / therapeutic use. Prostatic Neoplasms / drug therapy. Quality of Life. Surveys and Questionnaires

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Arch Esp Urol. 2009 Sep;62(7):543-70 [19815968.001]
  • (PMID = 20306583.001).
  • [ISSN] 1576-8260
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Comment; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Androgen Antagonists
  •  go-up   go-down


22. Boswell JS, Davis MD: Violaceous plaque on the forehead clinically resembling angiosarcoma: cutaneous metastasis in a patient with prostatic adenocarcinoma. J Am Acad Dermatol; 2005 Oct;53(4):744-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Violaceous plaque on the forehead clinically resembling angiosarcoma: cutaneous metastasis in a patient with prostatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Hemangiosarcoma / diagnosis. Prostatic Neoplasms / pathology. Skin Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16198815.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down


23. Williams K, Fernandez S, Stien X, Ishii K, Love HD, Lau YF, Roberts RL, Hayward SW: Unopposed c-MYC expression in benign prostatic epithelium causes a cancer phenotype. Prostate; 2005 Jun 1;63(4):369-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unopposed c-MYC expression in benign prostatic epithelium causes a cancer phenotype.
  • BACKGROUND: We have sought to develop a new in vivo model of prostate carcinogenesis using human prostatic epithelial cell cultures.
  • Human prostate cancers frequently display DNA amplification in the 8q24 amplicon, which leads to an increase in the copy number of the c-MYC gene, a finding that suggests a role for c-MYC in human prostate carcinogenesis.
  • In addition overexpression of c-MYC in transgenic mouse models results in prostatic carcinogenesis.
  • METHODS: We took advantage of the ability of retroviruses to integrate foreign DNA into human prostatic epithelium (huPrE) to generate cell lines that overexpress the c-MYC protooncogene.
  • RESULTS: The resultant tissue displayed a phenotype consistent with a poorly differentiated human prostatic adenocarcinoma.
  • The neoplastic cells in the tumor expressed both androgen receptors (AR) and prostate-specific antigen (PSA), both characteristic markers of human prostate cancers.
  • Microarray analysis of human prostatic epithelial cells overexpression c-MYC identified a large number of differentially expressed genes some of which have been suggested to characterize a subset of human cancers that have myc overexpression.
  • Control grafts using either uninfected huPrE or using huPrE cells infected using an empty vector expressing a green fluorescent protein tag gave rise to well differentiated benign prostatic glandular ducts.
  • CONCLUSIONS: By using a retroviral infection strategy followed by tissue recombination we have created a model of human prostate cancer that demonstrates that the c-MYC gene is sufficient to induce carcinogenesis.
  • [MeSH-major] Adenocarcinoma / genetics. Prostate / cytology. Prostate / physiology. Prostatic Neoplasms / genetics. Proto-Oncogene Proteins c-myc / genetics

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley-Liss, Inc.
  • (PMID = 15937962.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA96403; United States / NCI NIH HHS / CA / P30 CA68485; United States / NIDDK NIH HHS / DK / P60 DK20593
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-myc; 147336-22-9 / Green Fluorescent Proteins
  •  go-up   go-down


24. Tu WH, Jensen K, Freiha F, Liao JC: A case of prostatic adenocarcinoma recurrence presenting as ductal carcinoma of the prostate. Nat Clin Pract Urol; 2008 Jan;5(1):55-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of prostatic adenocarcinoma recurrence presenting as ductal carcinoma of the prostate.
  • BACKGROUND: A 61-year-old man with a history of recurrent prostate cancer presented with obstructive urinary symptoms.
  • He had been diagnosed with locally invasive adenocarcinoma of the prostate 10 years previously and treated with neoadjuvant hormonal and external beam radiation therapies.
  • Because of the patient's rising PSA level, he had been started on goserelin 6 years after this diagnosis and bicalutamide 6 months before the current presentation.
  • Cystoscopic examination revealed hypervascular, large lateral prostatic lobes obstructing the bladder neck.
  • DIAGNOSIS: The patient underwent transurethral resection of the prostate.
  • Soon after the resection started, bilateral papillary tumors arising from the stroma of both prostatic lobes were uncovered.
  • Pathologic analysis confirmed the presence of ductal carcinoma of the prostate.
  • The patient was started on docetaxel-based chemotherapy for hormone refractory recurrence of prostate cancer as ductal carcinoma of the prostate.
  • [MeSH-major] Carcinoma, Ductal / diagnosis. Neoplasm Recurrence, Local. Prostatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18185514.001).
  • [ISSN] 1743-4289
  • [Journal-full-title] Nature clinical practice. Urology
  • [ISO-abbreviation] Nat Clin Pract Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Suzuki T, Togo Y, Yasuda K, Yamamoto H, Kokura K: [Prostate cancer in a relatively young adult: a case report]. Hinyokika Kiyo; 2008 Feb;54(2):139-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prostate cancer in a relatively young adult: a case report].
  • We report a case of prostate cancer in a 45-year-old.
  • The patient was found to have an elevated prostate specific antigen (PSA) level at a general health check and was referred to our division.
  • Transperineal needle biopsy of the prostate revealed adenocarcinoma at the bilateral lobe (Gleason score 3+4).
  • Patients younger than 45 with prostate cancer are rare, although the incidence of prostate cancer is increasing.
  • [MeSH-major] Adenocarcinoma. Prostatic Neoplasms


26. Rose A, Xu Y, Chen Z, Fan Z, Stamey TA, McNeal JE, Caldwell M, Peehl DM: Comparative gene and protein expression in primary cultures of epithelial cells from benign prostatic hyperplasia and prostate cancer. Cancer Lett; 2005 Sep 28;227(2):213-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative gene and protein expression in primary cultures of epithelial cells from benign prostatic hyperplasia and prostate cancer.
  • Primary cultures are widely used to investigate the disease-specific biology of prostate cancer and benign prostatic hyperplasia (BPH).
  • Gene expression profiles were evaluated on Affymetrix Human Cancer G110 Array Chips containing approximately 1900 cancer-related genes.
  • After defined statistical analysis, genes that were over-expressed in cancer cultures were identified.
  • While no gene or protein was consistently over-expressed in all cancer versus BPH cell cultures, cytokeratin 16 protein was highly elevated in several of the cancer cultures, suggesting that a hyperproliferative phenotype may be characteristic of prostate cancer cells.
  • [MeSH-major] Adenocarcinoma / genetics. Biomarkers, Tumor / metabolism. Gene Expression Profiling. Oligonucleotide Array Sequence Analysis. Prostatic Hyperplasia / genetics. Prostatic Neoplasms / genetics


27. Hameed O, Sublett J, Humphrey PA: Immunohistochemical stains for p63 and alpha-methylacyl-CoA racemase, versus a cocktail comprising both, in the diagnosis of prostatic carcinoma: a comparison of the immunohistochemical staining of 430 foci in radical prostatectomy and needle biopsy tissues. Am J Surg Pathol; 2005 May;29(5):579-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical stains for p63 and alpha-methylacyl-CoA racemase, versus a cocktail comprising both, in the diagnosis of prostatic carcinoma: a comparison of the immunohistochemical staining of 430 foci in radical prostatectomy and needle biopsy tissues.
  • The diagnosis of prostatic carcinoma and especially minimal prostatic carcinoma can sometimes be challenging on needle core biopsy and occasionally immunohistochemistry is an aid in the diagnosis.
  • A retrospective review of 31 consecutive radical prostatectomy specimens and 150 prostate needle biopsy samples was performed to select histologic sections showing foci of prostatic carcinoma and/or minimal prostatic carcinoma, high-grade prostatic intraepithelial neoplasia (HGPIN), as well as common benign mimickers of prostatic carcinoma, to include atrophy and basal cell hyperplasia, especially with prominent nucleoli.
  • The cocktail was very useful in highlighting prostatic carcinoma associated with HGPIN, flat and cribriform HGPIN, and distorted foci of minimal prostatic carcinoma.
  • These data indicate that use of a p63/AMACR cocktail is essentially equivalent to use of each antibody separately for immunohistochemical confirmation of a diagnosis of prostatic carcinoma in needle biopsy.
  • This cocktail would be of diagnostic utility when only limited tissue is available for immunohistochemical evaluation of small, diagnostically difficult foci in prostate needle biopsy tissue.
  • [MeSH-major] Adenocarcinoma / chemistry. Fluorescent Antibody Technique, Indirect. Membrane Proteins / analysis. Prostatic Intraepithelial Neoplasia / chemistry. Prostatic Neoplasms / chemistry. Racemases and Epimerases / analysis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15832080.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Clinical Conference; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Membrane Proteins; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


28. Castellón E, Venegas K, Sáenz L, Contreras H, Huidobro C: Secretion of prostatic specific antigen, proliferative activity and androgen response in epithelial-stromal co-cultures from human prostate carcinoma. Int J Androl; 2005 Feb;28(1):39-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secretion of prostatic specific antigen, proliferative activity and androgen response in epithelial-stromal co-cultures from human prostate carcinoma.
  • We investigate the proliferative activity, prostatic specific antigen (PSA) secretion, morphology and androgen response of human prostate tumour epithelial cells co-cultured with stromal cells in a bicameral system.
  • Stromal and epithelial cells were isolated from prostate adenocarcinoma by enzyme digestion and cultured in defined media.
  • Immunocytochemistry for prostate carcinoma tumour antigen (PCTA-1) was performed for culture purity evaluation.
  • Primary co-cultures of epithelial and stromal cells from human prostate carcinoma are able to maintain, for a prolonged time, proliferative and secretory properties as well hormone response, and represent a valuable tool for cellular and molecular studies on prostate cancer.
  • [MeSH-major] Epithelial Cells / immunology. Prostate-Specific Antigen / secretion. Prostatic Neoplasms / immunology. Stromal Cells / immunology


29. Schostak M, Miller K, Krause H, Schrader M, Kempkensteffen C, Kollermann J: Kinetic fluorescence reverse transcriptase-polymerase chain reaction for alpha-methylacyl CoA racemase distinguishes prostate cancer from benign lesions. Cancer Detect Prev; 2006;30(5):449-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kinetic fluorescence reverse transcriptase-polymerase chain reaction for alpha-methylacyl CoA racemase distinguishes prostate cancer from benign lesions.
  • BACKGROUND: High-throughput gene expression profiling has recently shown that the mRNA for alpha-methylacyl CoA racemase (AMACR or P504S) is overexpressed in prostate carcinomas (PCa).
  • Several immunohistochemical studies have reported the usefulness of anti-AMACR/P504S for detecting prostate cancer over the full range of prostate specimens encountered in surgical pathology.
  • We tested real-time reverse transcriptase-polymerase chain reaction (RT-PCR) for specific and sensitive detection of AMACR transcripts as a supplementary measure for discriminating between malignant and benign lesions in prostatic tissues.
  • METHODS: Total RNA was isolated from snap-frozen chips in 55 cases of benign prostatic hyperplasia (BPH) and from frozen sections in 57 prostatectomy cases.
  • RESULTS: Normalized AMACR transcript levels showed an average 3.75-fold increase in 57 prostate carcinomas cases when compared to 55 cases of BPH (p<0.0001).
  • DISCUSSION: The present study demonstrates the usefulness of quantitative AMACR-mRNA transcript detection in prostatic tissues as an alternative to immunological staining techniques.
  • Since the latter clearly predominate in the laboratory routine, PCR-based detection of AMACR has the potential to gain widespread acceptance as a suitable future tool for monitoring prostate cancer patients.
  • [MeSH-major] Biomarkers, Tumor. Prostatic Hyperplasia / diagnosis. Prostatic Neoplasms / diagnosis. Racemases and Epimerases / genetics. Reverse Transcriptase Polymerase Chain Reaction
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / enzymology. Adenocarcinoma / secondary. Fluorescence. Humans. Kinetics. Male. Prostatectomy. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. ROC Curve. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17067752.001).
  • [ISSN] 0361-090X
  • [Journal-full-title] Cancer detection and prevention
  • [ISO-abbreviation] Cancer Detect. Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


30. Sakuma T, Yoshida T, Ohashi H, Nishimura K, Kawano K: [Combined small-cell carcinoma/adenocarcinoma of prostate: report of two cases]. Hinyokika Kiyo; 2007 Jul;53(7):489-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combined small-cell carcinoma/adenocarcinoma of prostate: report of two cases].
  • We report two cases of combined small-cell carcinoma (SCC) and adenocarcinoma of prostate.
  • Whole body computed tomography (CT) revealed prostatic swelling, pancreatic mass, para-aortic lymphadenopathies, and multiple lung nodules.
  • Elevation of tumor markers (prostate specific antigen [PSA, 1,760 ng/ml] and neuron-specific enolase [NSE, 88 ng/ml]) was noted.
  • Needle biopsy of the prostate demonstrated both SCC and adenocarcinoma.
  • The patient died three months after the diagnosis.
  • The symptom and elevated serum PSA (23.1 ng/ml) prompted prostatic needle biopsy, which demonstrated combined SCC/adenocarcinoma.
  • Treatment of combined SCC and adenocarcinoma of prostate poses a dilemma.
  • In Case 1, MAB was effective for adenocarcinoma but not for SCC.
  • Much remains to be elucidated to better manage combined SCC/adenocarcinoma of prostate.
  • [MeSH-major] Adenocarcinoma. Carcinoma, Small Cell. Neoplasms, Multiple Primary. Prostatic Neoplasms
  • [MeSH-minor] Aged. Androgen Antagonists / therapeutic use. Biomarkers, Tumor / blood. Fatal Outcome. Humans. Male. Phosphopyruvate Hydratase / blood. Prostate-Specific Antigen / blood. Treatment Outcome


31. Adolf K, Wagner L, Bergh A, Stattin P, Ottosen P, Borre M, Birkenkamp-Demtröder K, Orntoft TF, Tørring N: Secretagogin is a new neuroendocrine marker in the human prostate. Prostate; 2007 Apr 1;67(5):472-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secretagogin is a new neuroendocrine marker in the human prostate.
  • BACKGROUND: Neuroendocrine (NE) differentiation in prostate cancer (PCa), promoted by NE cell secreted products, appears to be associated with tumor progression, poor prognosis, and hormone-refractory disease.
  • The present study analyzes the expression of secretagogin in normal and malign prostate tissue.
  • METHODS: We analyzed immunoreactivity for secretagogin, chromogranin A (CgA), neuron specific enolase (NSE), and synaptophysin (SYN) in consecutive sections from 87 formalin-fixed paraffin-embedded (FFPE) benign hyperplastic (n = 10) and prostate adenocarcinoma (n = 77) specimens.
  • RESULTS: Secretagogin is cytoplasmic and nuclear expressed in NE and NE differentiated cells, and to a lesser extent in epithelial cells, in the benign prostate and prostate adenocarcinoma cells.
  • Secretagogin stained 82% (46/56) of benign and 71% (48/68) of prostate adenocarcinomas and co-localized with the NE markers CgA and NSE.
  • The expression of secretagogin is significantly correlated to CgA (P < 0.001) and NSE (P < 0.048) in prostate adenocarcinoma and to CgA in normal epithelium (P < 0.028).
  • CONCLUSIONS: Secretagogin is a novel NE marker in the prostate with more extended immunoreactivity compared to the NE markers CgA, SYN, and NSE.
  • Secretagogin is widely expressed in prostatic adenocarcinoma as opposed to adenocarcinomas in other organs.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / biosynthesis. Calcium-Binding Proteins / biosynthesis. Prostatic Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17285592.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Calcium-Binding Proteins; 0 / Chromogranin A; 0 / SCGN protein, human; 0 / Secretagogins; 0 / Synaptophysin; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


32. Elo TD, Valve EM, Seppänen JA, Vuorikoski HJ, Mäkelä SI, Poutanen M, Kujala PM, Härkönen PL: Stromal activation associated with development of prostate cancer in prostate-targeted fibroblast growth factor 8b transgenic mice. Neoplasia; 2010 Nov;12(11):915-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stromal activation associated with development of prostate cancer in prostate-targeted fibroblast growth factor 8b transgenic mice.
  • Expression of fibroblast growth factor 8 (FGF-8) is commonly increased in prostate cancer.
  • Experimental studies have provided evidence that it plays a role in prostate tumorigenesis and tumor progression.
  • To study how increased FGF-8 affects the prostate, we generated and analyzed transgenic (TG) mice expressing FGF-8b under the probasin promoter that targets expression to prostate epithelium.
  • Prostates of the TG mice showed an increased size and changes in stromal and epithelial morphology progressing from atypia and prostatic intraepithelial neoplasia (mouse PIN, mPIN) lesions to tumors with highly variable phenotype bearing features of adenocarcinoma, carcinosarcoma, and sarcoma.
  • In conclusion, our data demonstrate that disruption of FGF signaling pathways by increased epithelial production of FGF-8b leads to strongly activated and atypical stroma, which precedes development of mPIN lesions and prostate cancer with mixed features of adenocarcinoma and sarcoma in the prostates of TG mice.
  • The results suggest that increased FGF-8 in human prostate may also contribute to prostate tumorigenesis by stromal activation.
  • [MeSH-major] Fibroblast Growth Factor 8 / genetics. Prostate / metabolism. Prostatic Intraepithelial Neoplasia / genetics. Prostatic Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma / pathology. Animals. Connective Tissue Growth Factor / genetics. Connective Tissue Growth Factor / metabolism. Epithelial Cells / metabolism. Epithelial Cells / pathology. Female. Gene Expression Profiling. Humans. Immunohistochemistry. In Situ Hybridization. Male. Mice. Mice, Inbred C57BL. Mice, Inbred DBA. Mice, Transgenic. Oligonucleotide Array Sequence Analysis. Osteopontin / genetics. Osteopontin / metabolism. Protein Isoforms / genetics. Protein Isoforms / metabolism. Receptors, Androgen / genetics. Receptors, Androgen / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Sarcoma / pathology. Stromal Cells / metabolism. Stromal Cells / pathology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2000 Dec 1;88(5):718-25 [11072239.001]
  • [Cites] J Pathol. 2010 Mar;220(4):452-60 [19960500.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):4229-37 [11358849.001]
  • [Cites] Lab Invest. 2001 Jun;81(6):815-26 [11406643.001]
  • [Cites] Oncogene. 2001 May 17;20(22):2791-804 [11420691.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Oncogene. 2002 Mar 14;21(12):1899-908 [11896623.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3298-307 [12036948.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):442-54 [12189386.001]
  • [Cites] Cancer Res. 2002 Sep 1;62(17):5096-105 [12208767.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2912-23 [12231536.001]
  • [Cites] Br J Cancer. 2003 May 6;88(9):1432-8 [12778074.001]
  • [Cites] Int J Cancer. 2003 Oct 20;107(1):1-10 [12925950.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6237-43 [14559809.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4792-801 [14581350.001]
  • [Cites] Prostate. 2004 Jan 1;58(1):1-12 [14673947.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8256-63 [14678983.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8784-90 [14695195.001]
  • [Cites] Prostate. 2004 Feb 1;58(2):103-8 [14716735.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2270-305 [15026373.001]
  • [Cites] J Androl. 2004 Jul-Aug;25(4):564-72 [15223845.001]
  • [Cites] Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6169-78 [15448004.001]
  • [Cites] Endocrinology. 1991 Dec;129(6):3187-99 [1954898.001]
  • [Cites] Mol Cell Biol. 1993 Aug;13(8):4513-22 [7687739.001]
  • [Cites] Biochem Biophys Res Commun. 1994 Oct 28;204(2):882-8 [7980556.001]
  • [Cites] Cell Growth Differ. 1995 Jul;6(7):817-25 [7547503.001]
  • [Cites] Development. 1995 Nov;121(11):3603-13 [8582274.001]
  • [Cites] Oncogene. 1996 Apr 18;12(8):1833-5 [8622905.001]
  • [Cites] Genomics. 1996 Jul 1;35(1):253-7 [8661131.001]
  • [Cites] Cancer Res. 1998 May 15;58(10):2053-6 [9605740.001]
  • [Cites] Oncogene. 1999 Jan 28;18(4):1053-60 [10023681.001]
  • [Cites] Oncogene. 1999 Apr 29;18(17):2755-61 [10348350.001]
  • [Cites] Endocr Relat Cancer. 2004 Dec;11(4):709-24 [15613447.001]
  • [Cites] Br J Cancer. 2005 Jan 31;92(2):320-7 [15655558.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):8887-95 [16204060.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):883-8 [16424021.001]
  • [Cites] J Biol Chem. 2006 Jun 9;281(23):15694-700 [16597617.001]
  • [Cites] Int J Oncol. 2006 Dec;29(6):1591-9 [17089001.001]
  • [Cites] Mod Pathol. 2007 Jan;20(1):148-58 [17170745.001]
  • [Cites] Prostate. 2007 Feb 15;67(3):330-40 [17192877.001]
  • [Cites] Mod Pathol. 2007 Feb;20(2):175-82 [17192792.001]
  • [Cites] J Pathol. 2007 Sep;213(1):82-90 [17607666.001]
  • [Cites] Cancer Cell. 2007 Dec;12(6):559-71 [18068632.001]
  • [Cites] Cancer Cell. 2007 Dec;12(6):572-85 [18068633.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):22-31 [18386787.001]
  • [Cites] Mol Cell Endocrinol. 2008 Jul 16;289(1-2):38-48 [18455292.001]
  • [Cites] J Clin Invest. 2008 Aug;118(8):2697-710 [18618013.001]
  • [Cites] Clin Cancer Res. 2008 Nov 15;14(22):7470-80 [19010864.001]
  • [Cites] Endocr Relat Cancer. 2008 Dec;15(4):841-9 [18667687.001]
  • [Cites] Cytokine Growth Factor Rev. 2008 Oct-Dec;19(5-6):333-45 [18952487.001]
  • [Cites] Cancer Res. 2009 Feb 1;69(3):1230-9 [19155301.001]
  • [Cites] Nat Rev Drug Discov. 2009 Mar;8(3):235-53 [19247306.001]
  • [Cites] Prostate. 2009 Jun 1;69(8):799-809 [19189305.001]
  • [Cites] J Cell Biochem. 2009 Jul 1;107(4):769-84 [19415685.001]
  • [Cites] Endocrinology. 2000 Dec;141(12):4698-710 [11108285.001]
  • (PMID = 21076617.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Ctgf protein, mouse; 0 / FGF8 protein, human; 0 / Protein Isoforms; 0 / Receptors, Androgen; 0 / Spp1 protein, mouse; 106441-73-0 / Osteopontin; 139568-91-5 / Connective Tissue Growth Factor; 148997-75-5 / Fibroblast Growth Factor 8
  • [Other-IDs] NLM/ PMC2978914
  •  go-up   go-down


33. Wong SY, Crowley D, Bronson RT, Hynes RO: Analyses of the role of endogenous SPARC in mouse models of prostate and breast cancer. Clin Exp Metastasis; 2008;25(2):109-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analyses of the role of endogenous SPARC in mouse models of prostate and breast cancer.
  • Our recent gene expression analyses have shown that SPARC is significantly downregulated in highly metastatic human prostate cancer cells.
  • To test the role of endogenous SPARC in tumorigenesis directly, we examined cancer progression and metastasis in SPARC(+/-) and SPARC(-/-) mice using two separate transgenic mouse tumor models: transgenic adenocarcinoma of the mouse prostate (TRAMP) and murine mammary tumor virus-polyoma middle T (MMTV-PyMT).
  • Our results indicate that, although differential SPARC expression may be a useful marker of aggressive, metastasis-prone tumors, loss of SPARC is not sufficient either to promote or to inhibit cancer progression in two spontaneous mouse tumor models.

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 1999 Sep-Oct;19(5B):4199-202 [10628375.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):1140-9 [10741745.001]
  • [Cites] Matrix Biol. 2001 Jan;19(8):816-27 [11223341.001]
  • [Cites] J Clin Invest. 2001 Apr;107(7):785-90 [11285293.001]
  • [Cites] J Clin Invest. 2001 May;107(9):1049-54 [11342565.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):609-22 [11485919.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):5974-8 [11507037.001]
  • [Cites] Nature. 2001 Aug 23;412(6849):822-6 [11518967.001]
  • [Cites] Genome Biol. 2001;2(8):RESEARCH0032 [11532216.001]
  • [Cites] J Urol. 2001 Dec;166(6):2495-9 [11696817.001]
  • [Cites] J Histochem Cytochem. 2002 Jan;50(1):1-10 [11748289.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • [Cites] J Clin Invest. 2003 Feb;111(4):487-95 [12588887.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):537-49 [12842083.001]
  • [Cites] J Biol Chem. 2003 Oct 3;278(40):39044-50 [12885781.001]
  • [Cites] Mol Biol Cell. 2003 Oct;14(10):3977-88 [14517312.001]
  • [Cites] Bioinformatics. 2003 Nov 1;19(16):2065-71 [14594711.001]
  • [Cites] J Exp Med. 2003 Nov 17;198(10):1475-85 [14610043.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):811-6 [14711987.001]
  • [Cites] Neoplasia. 2004 Jan-Feb;6(1):1-6 [15068665.001]
  • [Cites] Mol Cancer Res. 2004 Apr;2(4):215-24 [15140943.001]
  • [Cites] J Cell Biochem. 2004 Jul 1;92(4):679-90 [15211566.001]
  • [Cites] J Invest Dermatol. 2004 Sep;123(3):592-9 [15304102.001]
  • [Cites] Invest Urol. 1979 Jul;17(1):16-23 [447482.001]
  • [Cites] J Cell Biol. 1989 Jul;109(1):341-56 [2745554.001]
  • [Cites] Mol Cell Biol. 1992 Mar;12(3):954-61 [1312220.001]
  • [Cites] J Cell Biol. 1993 Jun;121(6):1433-44 [8509459.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3439-43 [7724580.001]
  • [Cites] Mol Biol Cell. 1995 Mar;6(3):327-43 [7612967.001]
  • [Cites] Nat Med. 1997 Feb;3(2):171-6 [9018235.001]
  • [Cites] J Cell Physiol. 1997 Dec;173(3):327-34 [9369945.001]
  • [Cites] Prostate. 1998 Feb 15;34(3):169-74 [9492844.001]
  • [Cites] J Cell Biochem. 1998 Sep 15;70(4):543-52 [9712151.001]
  • [Cites] J Biol Chem. 1998 Nov 6;273(45):29635-40 [9792673.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1998 Dec;39(13):2674-80 [9856777.001]
  • [Cites] J Pathol. 1999 Sep;189(1):46-52 [10451487.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4453-7 [10485497.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):332-7 [15549095.001]
  • [Cites] Br J Cancer. 2004 Nov 29;91(11):1924-30 [15558074.001]
  • [Cites] Int J Cancer. 2005 Feb 20;113(5):789-97 [15499618.001]
  • [Cites] J Clin Invest. 2005 Jun;115(6):1492-502 [15902309.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7370-7 [16103089.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9789-98 [16267000.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):310-6 [16052522.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7516-23 [16885349.001]
  • [Cites] Oncogene. 2007 Jul 5;26(31):4513-22 [17260013.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12784-9 [17640904.001]
  • [Cites] Gut. 2007 Oct;56(10):1410-4 [17299058.001]
  • [Cites] Curr Protoc Immunol. 2001 Nov;Chapter 20:Unit 20.5 [18432778.001]
  • (PMID = 18058030.001).
  • [ISSN] 0262-0898
  • [Journal-full-title] Clinical & experimental metastasis
  • [ISO-abbreviation] Clin. Exp. Metastasis
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA017007; United States / NCI NIH HHS / CA / R01CA17007; United States / NCI NIH HHS / CA / U54 CA112967; United States / NCI NIH HHS / CA / R01 CA017007-30; United States / NCI NIH HHS / CA / U54-CA112967; United States / Howard Hughes Medical Institute / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, Polyomavirus Transforming; 0 / Osteonectin; 9007-34-5 / Collagen
  • [Other-IDs] NLM/ NIHMS345773; NLM/ PMC3252392
  •  go-up   go-down


34. Singh PB, Matanhelia SS, Martin FL: A potential paradox in prostate adenocarcinoma progression: oestrogen as the initiating driver. Eur J Cancer; 2008 May;44(7):928-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A potential paradox in prostate adenocarcinoma progression: oestrogen as the initiating driver.
  • One in 10 men in the developed world will present with prostate cancer (CaP), and in an ageing population developing strategies for its chemoprevention or treatment is of significance.
  • Orchidectomy or drug-induced reduction of serum testosterone levels with the consequent removal of growth-promoting effects in the prostate is the driving rationale for this regimen.
  • If so, elevated serum E2 levels could result in its increased conversion to genotoxic catechol oestrogens in target tissues such as the prostate.
  • [MeSH-major] Adenocarcinoma / etiology. Estrogens / physiology. Prostatic Neoplasms / etiology
  • [MeSH-minor] Androgen Antagonists / therapeutic use. Androgens / physiology. Antineoplastic Agents, Hormonal / therapeutic use. Disease Progression. Environmental Exposure. Gonadal Steroid Hormones / physiology. Humans. Male. Obesity / complications. Prostate / growth & development. Receptors, Estrogen / physiology. Selective Estrogen Receptor Modulators

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18381236.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Androgens; 0 / Antineoplastic Agents, Hormonal; 0 / Estrogens; 0 / Gonadal Steroid Hormones; 0 / Receptors, Estrogen; 0 / Selective Estrogen Receptor Modulators
  • [Number-of-references] 132
  •  go-up   go-down


35. Schiavo N, Lottermann AL, Costa FP, Staub HL: Antiphospholipid antibodies, thrombosis, and adenocarcinoma. Clinics (Sao Paulo); 2005 Jun;60(3):257-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antiphospholipid antibodies, thrombosis, and adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / blood. Antibodies, Antiphospholipid / blood. Lung Neoplasms / blood. Prostatic Neoplasms / blood. Venous Thrombosis / blood


36. Rabah DM, Arafa MA: Prostate cancer screening in a Saudi population: an explanatory trial study. Prostate Cancer Prostatic Dis; 2010 Jun;13(2):191-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate cancer screening in a Saudi population: an explanatory trial study.
  • The aim of this study is to explore the actual situation of prostate cancer in a cohort of healthy population in Saudi Arabia and to show the feasibility of screening for this disease using the internationally agreed criteria.
  • When either test was abnormal, transrectal ultrasound and multiple prostatic biopsies were performed for confirmation of the results.
  • Fifty two subjects had a positive diagnosis of prostatic adenocarcinoma, which compromised 2.5% of the cohort studied.
  • The cancer in 27 (52%) persons was organ confined, whereas in 14 (26.9%), it was metastatic.
  • The prevalence rate of prostate cancer detected by screening was higher than expected and the disease was advanced.
  • [MeSH-major] Biomarkers, Tumor / blood. Early Detection of Cancer / methods. Prostate-Specific Antigen / blood. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Adult. Age Factors. Aged. Cohort Studies. Digital Rectal Examination. Humans. Male. Middle Aged. Prostate / pathology. Saudi Arabia / epidemiology


37. Reddy S, Bang RH, Contreras ME: Telangiectatic cutaneous metastasis from carcinoma of the prostate. Br J Dermatol; 2007 Mar;156(3):598-600
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Telangiectatic cutaneous metastasis from carcinoma of the prostate.
  • [MeSH-major] Adenocarcinoma / secondary. Prostatic Neoplasms. Skin Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17300266.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter; Review
  • [Publication-country] England
  • [Number-of-references] 29
  •  go-up   go-down


38. Bauman DR, Steckelbroeck S, Peehl DM, Penning TM: Transcript profiling of the androgen signal in normal prostate, benign prostatic hyperplasia, and prostate cancer. Endocrinology; 2006 Dec;147(12):5806-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcript profiling of the androgen signal in normal prostate, benign prostatic hyperplasia, and prostate cancer.
  • Human prostate adenocarcinoma (CaP) and benign prostatic hyperplasia (BPH) have epithelial and stromal cell origins, respectively.
  • Transcripts for type 2 5alpha-reductase, ketosteroid reductases [aldo-keto reductase (AKR)1C1-AKR1C4], the major oxidative 3alpha-hydroxysteroid dehydrogenase (HSD) retinol dehydrogenase (RODH)-like 3alpha-HSD (RL-HSD) and nuclear receptors [AR, estrogen receptor (ER)alpha, and ERbeta] were determined in whole human prostate and in cultures of primary epithelial cells (PEC) and primary stromal cells (PSC) from normal prostate, CaP and BPH by real-time RT-PCR.
  • Differences in the AR:ERbeta transcript ratios (eight in normal PEC vs. 280 in normal PSC) were maintained in PEC and PSC in diseased prostate.
  • [MeSH-major] Androgens / metabolism. Carcinoma / metabolism. Gene Expression Profiling / methods. Prostate / metabolism. Prostatic Hyperplasia / metabolism. Prostatic Neoplasms / metabolism


39. Hussein K, Nanda A, Al-Sabah H, Alsaleh QA: Sweet's syndrome (acute febrile neutrophilic dermatosis) associated with adenocarcinoma of prostate and transitional cell carcinoma of urinary bladder. J Eur Acad Dermatol Venereol; 2005 Sep;19(5):597-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sweet's syndrome (acute febrile neutrophilic dermatosis) associated with adenocarcinoma of prostate and transitional cell carcinoma of urinary bladder.
  • In the present report, we describe an 82-year-old male with SS in association with adenocarcinoma of the prostate and transitional cell carcinoma of the urinary bladder.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Transitional Cell / pathology. Neoplasms, Multiple Primary / diagnosis. Prostatic Neoplasms / pathology. Sweet Syndrome / diagnosis. Urinary Bladder Neoplasms / pathology


40. Trivunić S, Budakov P, Vucković N, Zivojinov M: [Morphological parameters of prostatic adenocarcinoma]. Med Pregl; 2007 Nov-Dec;60(11-12):549-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Morphological parameters of prostatic adenocarcinoma].
  • INTRODUCTION: Prostatic carcinoma is one of the most common malignancies in men and the second most common cause of cancer-related deaths, after lung cancer.
  • PROSTATIC CARCINOMA: HISTOLOGIC FEATURES: Prostatic carcinomas have multiple histologic patterns, which can easily be confused with benign lesions.
  • The following histologic changes are associated with prostatic carcinomas. prostatic acini are close to one another and present with linear infiltrates in the fibromuscular tissue; cells lining the acini often consist of a single layer, and the basal cell layer is absent; prominent large eosinophilic nucleoli are usually present in malignant cells; nuclear hyperchromatism is rare and it depends on the quality of the tissue fixation; perineural invasion is often observed.
  • Immunohistochemistry is widely used in pathology and clinical diagnosis of prostatic carcinoma, metastases of prostatic origin in staging malignant tumors and in the prognosis.
  • [MeSH-major] Adenocarcinoma / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18666594.001).
  • [ISSN] 0025-8105
  • [Journal-full-title] Medicinski pregled
  • [ISO-abbreviation] Med. Pregl.
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


41. Karsenty G, Rocha J, Chevalier S, Scarlata E, Andrieu C, Zouanat FZ, Rocchi P, Giusiano S, Elzayat EA, Corcos J: Botulinum toxin type A inhibits the growth of LNCaP human prostate cancer cells in vitro and in vivo. Prostate; 2009 Aug 1;69(11):1143-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Botulinum toxin type A inhibits the growth of LNCaP human prostate cancer cells in vitro and in vivo.
  • INTRODUCTION AND OBJECTIVE: Botulinum toxin type A (BTA) intraprostatic injection induces an improvement of urinary symptoms related to benign prostatic hypertrophy (BPH).
  • Infra-clinical prostate cancer (PCa) foci and pre-neoplasic lesions occur concomitantly with BPH in a significant number of patients.
  • The objective of this study was to address whether BTA influences the growth of prostate tumors.
  • These findings indicate that intra-prostatic BTA injections to treat BPH are unlikely to promote the growth of co-existing infra-clinical PCa foci in men.
  • [MeSH-major] Adenocarcinoma / pathology. Botulinum Toxins, Type A / pharmacology. Cell Proliferation / drug effects. Neurotoxins / pharmacology. Prostatic Neoplasms / pathology


42. Weinreb JC, Blume JD, Coakley FV, Wheeler TM, Cormack JB, Sotto CK, Cho H, Kawashima A, Tempany-Afdhal CM, Macura KJ, Rosen M, Gerst SR, Kurhanewicz J: Prostate cancer: sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy--results of ACRIN prospective multi-institutional clinicopathologic study. Radiology; 2009 Apr;251(1):122-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate cancer: sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy--results of ACRIN prospective multi-institutional clinicopathologic study.
  • PURPOSE: To determine the incremental benefit of combined endorectal magnetic resonance (MR) imaging and MR spectroscopic imaging, as compared with endorectal MR imaging alone, for sextant localization of peripheral zone (PZ) prostate cancer.
  • One hundred thirty-four patients with biopsy-proved prostate adenocarcinoma and scheduled to undergo radical prostatectomy were recruited at seven institutions.
  • Eight readers independently rated the likelihood of the presence of PZ cancer in each sextant by using a five-point scale-first on MR images alone and later on combined MR-MR spectroscopic images.
  • The presence or absence of cancer at centralized histopathologic evaluation of prostate specimens was the reference standard.
  • MR imaging alone and combined MR imaging-MR spectroscopic imaging had similar accuracy in PZ cancer localization (AUC, 0.60 vs 0.58, respectively; P > .05).
  • CONCLUSION: In patients who undergo radical prostatectomy, the accuracy of combined 1.5-T endorectal MR imaging-MR spectroscopic imaging for sextant localization of PZ prostate cancer is equal to that of MR imaging alone.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2000 Sep;164(3 Pt 1):759-63 [10953141.001]
  • [Cites] Radiology. 2003 Oct;229(1):241-7 [12920178.001]
  • [Cites] Annu Rev Public Health. 2001;22:91-113 [11274513.001]
  • [Cites] Magn Reson Med. 2001 Dec;46(6):1079-87 [11746572.001]
  • [Cites] Urology. 2001 Dec;58(6):843-8 [11744442.001]
  • [Cites] Radiology. 2002 Apr;223(1):91-7 [11930052.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-104-17 [12187175.001]
  • [Cites] J Natl Cancer Inst. 2003 Jul 2;95(13):981-9 [12837834.001]
  • [Cites] Invest Radiol. 2004 Nov;39(11):671-80 [15486528.001]
  • [Cites] N Engl J Med. 1990 Sep 6;323(10):621-6 [2200965.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2679-80 [7680952.001]
  • [Cites] Invest Radiol. 1994 Feb;29(2):238-43 [8169102.001]
  • [Cites] Radiology. 1994 Jul;192(1):47-54 [8208963.001]
  • [Cites] Prostate. 1994 Nov;25(5):274-9 [7526353.001]
  • [Cites] Radiology. 1999 Nov;213(2):473-80 [10551229.001]
  • [Cites] Radiology. 1999 Nov;213(2):481-8 [10551230.001]
  • [Cites] Magn Reson Med. 2000 Jan;43(1):23-33 [10642728.001]
  • [Cites] Radiology. 1995 Jun;195(3):753-6 [7754006.001]
  • [Cites] Clin Radiol. 1995 Sep;50(9):593-600 [7554732.001]
  • [Cites] Radiology. 1996 Mar;198(3):795-805 [8628874.001]
  • [Cites] Radiology. 1996 Aug;200(2):489-96 [8685346.001]
  • [Cites] J Urol. 1997 Mar;157(3):902-6 [9072596.001]
  • [Cites] Radiology. 1997 Mar;202(3):697-702 [9051019.001]
  • [Cites] Urology. 1997 Mar;49(3A Suppl):84-94 [9123742.001]
  • [Cites] JAMA. 1997 May 14;277(18):1445-51 [9145716.001]
  • [Cites] Biometrics. 1997 Jun;53(2):567-78 [9192452.001]
  • [Cites] Stat Med. 1997 Jul 15;16(13):1529-42 [9249923.001]
  • [Cites] Eur Urol. 1997;32 Suppl 3:15-23 [9267782.001]
  • [Cites] Acad Radiol. 1995 Mar;2 Suppl 1:S22-9; discussion S57-64, S70-1 pas [9419702.001]
  • [Cites] Stat Methods Med Res. 1998 Dec;7(4):371-92 [9871953.001]
  • [Cites] J Urol. 1999 Feb;161(2):494-8; discussion 498-9 [9915434.001]
  • [Cites] Eur Urol. 1999 Apr;35(4):289-93 [10087390.001]
  • [Cites] JAMA. 1999 Apr 21;281(15):1395-400 [10217055.001]
  • [Cites] Radiology. 2004 Dec;233(3):701-8 [15564406.001]
  • [Cites] Radiology. 2005 Nov;237(2):541-9 [16244263.001]
  • [Cites] Radiology. 2006 Jan;238(1):192-9 [16373767.001]
  • [Cites] AJR Am J Roentgenol. 2006 Mar;186(3):729-42 [16498100.001]
  • [Cites] Radiology. 2006 Jun;239(3):784-92 [16569788.001]
  • [Cites] J Magn Reson Imaging. 2006 Jul;24(1):108-13 [16767709.001]
  • [Cites] Radiology. 2006 Nov;241(2):449-58 [16966484.001]
  • [Cites] Cancer. 2007 Apr 1;109(7):1273-8 [17315165.001]
  • [Cites] Radiology. 2007 Sep;244(3):797-806 [17652190.001]
  • [Cites] Radiology. 2008 Jan;246(1):177-84 [18024434.001]
  • [Cites] AJR Am J Roentgenol. 2001 Jan;176(1):17-22 [11133530.001]
  • (PMID = 19332850.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA059897; United States / NCI NIH HHS / CA / U01 CA079778; United States / NCI NIH HHS / CA / U01 CA080098
  • [Publication-type] Controlled Clinical Trial; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2663583
  •  go-up   go-down


43. Yang YS, Zhang X, Xiong Z, Chen X: Comparative in vitro and in vivo evaluation of two 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma. Nucl Med Biol; 2006 Apr;33(3):371-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative in vitro and in vivo evaluation of two 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma.
  • Overexpression of GRPR has been discovered in mostly androgen-independent human prostate tissues and, thus, provides a potential target for prostate cancer diagnosis and therapy.
  • We have previously demonstrated the feasibility of the positron emission tomography (PET) imaging using 64Cu-1,4,7,10-tetraazadodecane-N,N',N'',N'''-tetraacetic acid (DOTA)-[Lys3]BBN to detect GRPR-positive prostate cancer.
  • Binding of each DOTA conjugate to GRPR on PC-3 and 22Rv1 prostate cancer cells was evaluated with competitive binding assay using 125I-[Tyr4]BBN as radioligand.
  • This study demonstrated that both tracers are suitable for targeted PET imaging to detect the expression of GRPR in prostate cancer, while 64Cu-DOTA-[Lys3]BBN may have a better potential for clinical translation.
  • [MeSH-major] Bombesin. Copper Radioisotopes. Disease Models, Animal. Prostatic Neoplasms / radionuclide imaging
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / radionuclide imaging. Animals. Binding, Competitive. Humans. In Vitro Techniques. Male. Mice. Mice, Nude. Positron-Emission Tomography. Receptors, Bombesin / metabolism. Tissue Distribution

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16631086.001).
  • [ISSN] 0969-8051
  • [Journal-full-title] Nuclear medicine and biology
  • [ISO-abbreviation] Nucl. Med. Biol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA114747; United States / NCI NIH HHS / CA / R21 CA102123; United States / NIBIB NIH HHS / EB / R21 EB001785; United States / NCI NIH HHS / CA / R24 CA86307; United States / NCI NIH HHS / CA / R24 CA93862; United States / PHS HHS / / U54
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Copper Radioisotopes; 0 / Receptors, Bombesin; PX9AZU7QPK / Bombesin
  •  go-up   go-down


44. Kuefer R, Day KC, Kleer CG, Sabel MS, Hofer MD, Varambally S, Zorn CS, Chinnaiyan AM, Rubin MA, Day ML: ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease. Neoplasia; 2006 Apr;8(4):319-29
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease.
  • TMA analysis revealed that ADAM15 protein was significantly increased in multiple types of adenocarcinoma, specifically in prostate and breast cancer specimens.
  • Statistical association was observed with disease progression within clinical parameters of predictive outcome for both prostate and breast cancers, pertaining to Gleason sum and angioinvasion, respectively.
  • In this report, we also present data from a cDNA microarray of prostate cancer (PCa), where we compared transfected LNCaP cells that overexpress ADAM15 to vector control cells.
  • These results suggest that ADAM15 is generally overexpressed in adenocarcinoma and is highly associated with metastatic progression of prostate and breast cancers.

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2003 Jan 10;278(2):1372-9 [12393869.001]
  • [Cites] Genes Dev. 2003 Jan 1;17(1):7-30 [12514095.001]
  • [Cites] Neoplasia. 2003 May-Jun;5(3):218-28 [12869305.001]
  • [Cites] Mol Cell Biol. 2003 Aug;23(16):5614-24 [12897135.001]
  • [Cites] J Biol Chem. 2003 Aug 15;278(33):30469-77 [12777399.001]
  • [Cites] Curr Opin Cell Biol. 2003 Oct;15(5):598-606 [14519395.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6524-36 [14528277.001]
  • [Cites] Biochem Soc Trans. 2003 Dec;31(Pt 6):1203-8 [14641026.001]
  • [Cites] Oncogene. 2004 Jan 29;23(4):991-9 [14647423.001]
  • [Cites] Int J Cancer. 2004 Apr 10;109(3):363-9 [14961574.001]
  • [Cites] Oncol Rep. 2004 Apr;11(4):905-10 [15010893.001]
  • [Cites] Crit Rev Oncol Hematol. 2004 Mar;49(3):179-86 [15036258.001]
  • [Cites] Neoplasia. 2004 Jan-Feb;6(1):1-6 [15068665.001]
  • [Cites] J Clin Pathol. 2004 Jun;57(6):577-84 [15166260.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7237-40 [15492240.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):125-8 [5948714.001]
  • [Cites] Cancer. 1987 Jun 1;59(11):1918-22 [3032395.001]
  • [Cites] J Cell Biochem. 1987 Jul;34(3):187-202 [3611200.001]
  • [Cites] Genes Dev. 1995 Aug 1;9(15):1896-908 [7544313.001]
  • [Cites] J Cell Biol. 1995 Oct;131(2):275-8 [7593158.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Jun 18;235(2):437-42 [9199213.001]
  • [Cites] J Natl Cancer Inst. 1998 May 20;90(10):766-71 [9605647.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Eur J Cancer. 1998 Apr;34(5):646-53 [9713268.001]
  • [Cites] Science. 1998 Nov 13;282(5392):1281-4 [9812885.001]
  • [Cites] J Cell Sci. 1999 Feb;112 ( Pt 4):579-87 [9914169.001]
  • [Cites] J Clin Invest. 1999 May;103(9):1227-30 [10225964.001]
  • [Cites] Am J Pathol. 1999 May;154(5):1489-501 [10329602.001]
  • [Cites] J Biol Chem. 2004 Dec 3;279(49):51323-30 [15381692.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Jan;131(1):41-8 [15565459.001]
  • [Cites] Int J Oncol. 2005 Jan;26(1):17-24 [15586220.001]
  • [Cites] Int J Biochem Cell Biol. 2005 Mar;37(3):590-603 [15618016.001]
  • [Cites] Prostate. 2005 May 15;63(3):259-68 [15538719.001]
  • [Cites] Arthritis Rheum. 2005 Apr;52(4):1100-9 [15818704.001]
  • [Cites] Virchows Arch. 2005 Apr;446(4):421-9 [15756594.001]
  • [Cites] Int J Cancer. 2005 Jul 20;115(6):849-60 [15729716.001]
  • [Cites] Biol Chem. 2005 Sep;386(9):845-55 [16164409.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Dec;41(4):366-78 [15384173.001]
  • [Cites] Trends Genet. 2000 Feb;16(2):83-7 [10652535.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):1038-45 [10741732.001]
  • [Cites] Am J Pathol. 2000 Apr;156(4):1345-62 [10751360.001]
  • [Cites] FEBS Lett. 2000 May 19;473(3):275-9 [10818225.001]
  • [Cites] J Natl Cancer Inst. 2000 Jun 7;92(11):937-9 [10841830.001]
  • [Cites] Lab Invest. 2000 Jun;80(6):931-42 [10879743.001]
  • [Cites] Mol Cell Endocrinol. 2000 Sep 25;167(1-2):11-21 [11000516.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Nov 30;278(3):511-5 [11095942.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):489-92 [11212238.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4683-8 [11406537.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5692-6 [11479199.001]
  • [Cites] Nature. 2001 Aug 23;412(6849):822-6 [11518967.001]
  • [Cites] Urology. 2001 Sep;58(3):393-9 [11549487.001]
  • [Cites] J Pathol. 2002 Jan;196(1):8-16 [11748636.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):312-9 [11859202.001]
  • [Cites] J Biol Chem. 2002 Sep 13;277(37):33683-9 [12091380.001]
  • [Cites] Nature. 2002 Oct 10;419(6907):624-9 [12374981.001]
  • [Cites] World J Gastroenterol. 2002 Oct;8(5):769-76 [12378613.001]
  • [Cites] J Cell Biochem. 2003 Jul 1;89(4):808-23 [12858346.001]
  • (PMID = 16756724.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01CA107469; United States / NIDDK NIH HHS / DK / R01 DK56137-05; United States / NIDDK NIH HHS / DK / R01 DK056137; United States / NCI NIH HHS / CA / R01 CA107469; United States / NCI NIH HHS / CA / K08 CA090876
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / Membrane Proteins; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; EC 3.4.24.- / ADAM Proteins; EC 3.4.24.- / ADAM15 protein, human
  • [Other-IDs] NLM/ PMC1600681
  •  go-up   go-down


45. Zeng Y, Yokohira M, Takeuchi H, Saoo K, Yamakawa K, Matsuda Y, Hosokawa K, Li JQ, Ikeda M, Imaida K: Lack of significant modifying effect of arctiin on prostate carcinogenesis in probasin/SV40 T antigen transgenic rats. Cancer Lett; 2005 May 26;222(2):145-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of significant modifying effect of arctiin on prostate carcinogenesis in probasin/SV40 T antigen transgenic rats.
  • Modifying effects of arctiin on prostate carcinogenesis in probasin/SV 40 T antigen (Tag) transgenic (TG) rats were examined.
  • Histopathological evaluation of prostate revealed that all the rats in any group developed adenocarcinoma in dorsolateral lobe of prostate, except two rats in 0.1% arctiin treated and one rat in 0.002% arctiin treated groups without prostate adenocarcinoma development.
  • However, there were no definite treatment-related changes with statistical significance in all parameters for prostate carcinomas measured in this experiment.
  • These results indicated that arctiin might not exert significant modifying effect on prostate carcinogenesis in SV 40 Tag TG rats at least under the present experiment.
  • [MeSH-major] Adenoma / physiopathology. Furans / pharmacology. Glucosides / pharmacology. Prostatic Neoplasms / physiopathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15863263.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Androgen-Binding Protein; 0 / Antigens, Polyomavirus Transforming; 0 / Drugs, Chinese Herbal; 0 / Furans; 0 / Glucosides; 0 / probasin; TM5RQ949K7 / arctiin
  •  go-up   go-down


46. Srigley JR: Key issues in handling and reporting radical prostatectomy specimens. Arch Pathol Lab Med; 2006 Mar;130(3):303-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: Patients with prostatic adenocarcinoma commonly undergo radical prostatectomy, and it is often difficult and time consuming to handle the resulting specimens and to report the findings.
  • The prostate specimen must be handled in a systematic fashion to derive the appropriate prognostic parameters.
  • The synoptic style of reporting is ideal for describing complex cancer resection specimens.
  • A synoptic report based on an evidence-based checklist, such as the one developed by the College of American Pathologists, effectively communicates complex cancer-related data, such as radical prostatectomy specimen findings.
  • [MeSH-major] Adenocarcinoma / pathology. Medical Records / standards. Neoplasm Staging / standards. Pathology, Surgical / standards. Prostatic Neoplasms / pathology. Societies, Medical / standards. Specimen Handling / standards

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16519557.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Jaraj SJ, Egevad L: Formalin fixation and immunoreactivity in prostate cancer and benign prostatic tissues. APMIS; 2010 May;118(5):383-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Formalin fixation and immunoreactivity in prostate cancer and benign prostatic tissues.
  • A tissue microarray of cancer and benign tissues from 42 RP specimens was constructed.
  • IHC staining was performed using 15 antibodies, including nuclear and cytoplasmic markers known to be positive in prostate tissue: pan cytokeratin, P504S, high molecular weight (HMW) keratin, PSA, vimentin, actin HHF35, thioredoxin-1, peroxiredoxin-2, PDX-1, BAX, p27, androgen receptor (AR) and heat shock proteins (HSP) 27, 60 and 70.
  • Differences in staining intensity in cancer and benign tissues were compared separately except for HMW keratin.
  • For most antibodies, formalin injection does not significantly affect immunoreactivity in prostate tissue.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Immunohistochemistry / methods. Prostate / metabolism. Prostate / pathology. Prostatic Neoplasms / metabolism. Prostatic Neoplasms / pathology. Tissue Fixation / methods


48. Hsu IC, Bae K, Shinohara K, Pouliot J, Purdy J, Ibbott G, Speight J, Vigneault E, Ivker R, Sandler H: Phase II trial of combined high-dose-rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate: preliminary results of RTOG 0321. Int J Radiat Oncol Biol Phys; 2010 Nov 1;78(3):751-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of combined high-dose-rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate: preliminary results of RTOG 0321.
  • PURPOSE: To estimate the rate of late Grade 3 or greater genitourinary (GU) and gastrointestinal (GI) adverse events (AEs) after treatment with external beam radiotherapy and prostate high-dose-rate (HDR) brachytherapy.
  • Patients with locally confined Stage T1c-T3b prostate cancer were eligible for the present study.
  • The pretreatment characteristics of the patients were as follows: Stage T1c-T2c, 91%; Stage T3a-T3b, 9%; prostate-specific antigen level ≤10 ng/mL, 70%; prostate-specific antigen level >10 but ≤20 ng/mL, 30%; and Gleason score 2-6, 10%; Gleason score 7, 72%; and Gleason score 8-10, 18%.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):851-8 [10705005.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):814-9 [18407435.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 May 1;47(2):343-52 [10802358.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):61-9 [11163498.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 15;50(4):1021-31 [11429230.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jan 1;52(1):81-90 [11777625.001]
  • [Cites] J Urol. 2003 Mar;169(3):974-9; discussion 979-80 [12576825.001]
  • [Cites] Radiother Oncol. 2003 Sep;68(3):285-8 [13129636.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1063-71 [15001246.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Dec 1;33(5):1019-27 [7493828.001]
  • [Cites] Radiother Oncol. 1997 Sep;44(3):237-44 [9380822.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):525-33 [9635698.001]
  • [Cites] Radiother Oncol. 1998 Aug;48(2):197-202 [9783892.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Mar 15;43(5):1095-101 [10192361.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jul 1;44(4):747-8 [10386630.001]
  • [Cites] Strahlenther Onkol. 1999 Jun;175 Suppl 2:87-8 [10394408.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):804-9 [16289906.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2006;9(3):245-53 [16786040.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):416-23 [16879929.001]
  • [Cites] Cancer. 2007 Apr 15;109(8):1506-12 [17340591.001]
  • [Cites] Radiother Oncol. 2007 Aug;84(2):114-20 [17531335.001]
  • [Cites] J Appl Clin Med Phys. 2007;8(4):2415 [18449148.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 15;46(5):1205-11 [10725633.001]
  • (PMID = 20207506.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA32115; United States / NCI NIH HHS / CA / U24 CA081647; United States / NCI NIH HHS / CA / U10 CA21661; United States / NCI NIH HHS / CA / U10CA37422; United States / NCI NIH HHS / CA / U24 CA81647; United States / NCI NIH HHS / CA / U10 CA037422; United States / NCI NIH HHS / CA / U10 CA021661; United States / NCI NIH HHS / CA / U10 CA032115
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  • [Other-IDs] NLM/ NIHMS209285; NLM/ PMC2946454
  •  go-up   go-down


49. Sartor O, McLeod DG, Halabi S, Schellhammer PF, Scardino PT, D'Amico AV, Bennett C, Wei JT, COMPARE Registry Steering Committee: The COMPARE Registry: design and baseline patterns of care for men with biochemical failure after definitive treatment of localized prostate cancer. Urology; 2010 Mar;75(3):623-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The COMPARE Registry: design and baseline patterns of care for men with biochemical failure after definitive treatment of localized prostate cancer.
  • OBJECTIVES: To define current standards of care for patients with prostate-specific antigen (PSA) failure after initial definitive local treatment of prostate cancer using Comprehensive, Observational, Multicenter, Prostate Adenocarcinoma Registry (COMPARE).
  • This article describes the design of the COMPARE Registry, together with patient characteristics and prostate cancer management at enrolment.
  • METHODS: The COMPARE Registry is a prospective, multicenter, observational study that collected data on patient characteristics, management practices, and outcomes of men presenting to their physician for the management of an increasing PSA level after definitive (surgical or radiotherapeutic) treatment of localized prostate cancer.
  • The men had a median age of 73 years (range, 46-95 years), were predominantly white (77%), and had a median PSA level of 7.9 ng/mL (range, 0-710.8 ng/mL) at diagnosis.
  • CONCLUSIONS: Data from the COMPARE Registry should provide a valuable source of prospectively collected information on the contemporary management of prostate cancer and patient outcomes after PSA failure.
  • [MeSH-major] Adenocarcinoma / blood. Adenocarcinoma / therapy. Prostate-Specific Antigen / blood. Prostatic Neoplasms / blood. Prostatic Neoplasms / therapy. Registries

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19589569.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  • [Investigator] Bennett C; Brawley O; D'Amico A; Halabi S; Higano CS; Kattan M; Lilja H; McLeod DG; Metzger CK; Moul JW; Perez C; Petrylak D; Potters L; Powell I; Rayford W; Sartor O; Scardino PT; Scher H; Schellhammer P; Slawin K; Stone B; Wei JT
  •  go-up   go-down


50. D'Amico AV, Halabi S, Vollmer R, Loffredo M, McMahon E, Sanford B, Archer L, Vogelzang NJ, Small EJ, Kantoff PW, Cancer and Leukemia Group B: p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682). Urology; 2008 May;71(5):933-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682).
  • METHODS: Between May 1997 and April 2001, 180 men with clinical stage T1c-T3cN0M0 adenocarcinoma of the prostate were registered on a study evaluating whether the endorectal magnetic resonance imaging (eMRI)-defined change in tumor volume (TV) during neoadjuvant (n) AST was associated with prostate-specific antigen (PSA) outcome.
  • CONCLUSIONS: Maximizing local control and randomized trials evaluating the impact on survival of adding novel agents to maximal local therapy are warranted in men whose prostate cancer demonstrates abnormal p53 expression.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / therapy. Flutamide / therapeutic use. Gonadotropin-Releasing Hormone / agonists. Neoplasm Recurrence, Local / epidemiology. Prostatic Neoplasms / metabolism. Prostatic Neoplasms / therapy. Tumor Suppressor Protein p53 / biosynthesis

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18291508.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA03927; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA32291; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA41287; United States / NCI NIH HHS / CA / CA60138; United States / NCI NIH HHS / CA / CA77406; United States / NCI NIH HHS / CA / CA77651
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; 33515-09-2 / Gonadotropin-Releasing Hormone; 76W6J0943E / Flutamide
  •  go-up   go-down


51. De Matteis M, Poggi C, De Martino A, Corti B, Barozzi L, Pavlica P: Repeat biopsy in patients with initial diagnosis of PIN. Radiol Med; 2005 Sep;110(3):190-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Repeat biopsy in patients with initial diagnosis of PIN.
  • PURPOSE: Prostatic intra-epithelial neoplasia (PIN) is considered a pre-malignant lesion and the main precursor of invasive prostatic adenocarcinoma.
  • A PIN diagnosis established by prostate needle biopsy poses a difficult clinical management problem.
  • MATERIALS AND METHODS: We reviewed the repeat biopsy records of 72 patients in whom PIN had been detected on initial US-guided needle biopsy of the prostate.
  • RESULTS: Adenocarcinoma was detected in 15 patients out of 50 (30%) with an initial diagnosis of low-grade PIN and in 10 patients out of 22 (45.4%) with high grade PIN, in 7 out of 18 (39%) in whom PSA levels had decreased during the observation interval, in 16 patients out of 46 (35%) in whom the PSA had increased and in 2 patients out of 8 (25%) with stable PSA.
  • CONCLUSIONS: Our results seem to confirm that PIN can be considered a precursor of prostatic adenocarcinoma or a histological alteration often associated with it.
  • Patients with low-grade PIN and particularly those with high-grade PIN should be regularly subjected to repeat biopsy at short intervals due to the high frequency of the final diagnosis of carcinoma.
  • The PSA changes during the observation period are not a statistically significant parameter to suggest the repetition of prostatic biopsy.
  • [MeSH-major] Adenocarcinoma / pathology. Biopsy, Needle. Carcinoma / pathology. Prostate / pathology. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Follow-Up Studies. Humans. Male. Middle Aged. Prostate-Specific Antigen / analysis. Retrospective Studies. Time Factors

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16200041.001).
  • [ISSN] 0033-8362
  • [Journal-full-title] La Radiologia medica
  • [ISO-abbreviation] Radiol Med
  • [Language] eng; ita
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


52. Suzue K, Montag AG, Tretiakova M, Yang XJ, Sahoo S: Altered expression of alpha-methylacyl-coenzyme A racemase in prostatic adenocarcinoma following hormone therapy. Am J Clin Pathol; 2005 Apr;123(4):553-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Altered expression of alpha-methylacyl-coenzyme A racemase in prostatic adenocarcinoma following hormone therapy.
  • alpha-Methylacyl-coenzyme A racemase (AMACR) is a sensitive and specific tissue marker for the diagnosis of prostatic carcinoma.
  • However, limited data are available on AMACR expression in residual prostatic carcinoma following hormone therapy.
  • We analyzed 64 residual or recurrent prostatic adenocarcinomas following hormonal therapy for the expression of AMACR using a monoclonal antibody (P504S) to AMACR.
  • AMACR expression was reduced significantly in the majority of posthormonal residual carcinomas, whereas in postradiotherapy and in hormone-refractory metastatic prostatic adenocarcinoma, AMACR expression was retained.
  • Therefore, the diagnosis of residual prostatic carcinoma after hormonal therapy using AMACR immunostaining must be interpreted with caution.
  • Furthermore, AMACR might have a role in the recurrence of prostatic adenocarcinoma after medical therapy.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / therapy. Prostatic Neoplasms / metabolism. Prostatic Neoplasms / therapy. Racemases and Epimerases / biosynthesis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15743746.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Biomarkers, Tumor; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


53. Li W, Liu X, Wang W, Sun H, Hu Y, Lei H, Liu G, Gao Y: Effects of antisense RNA targeting of ODC and AdoMetDC on the synthesis of polyamine synthesis and cell growth in prostate cancer cells using a prostatic androgen-dependent promoter in adenovirus. Prostate; 2008 Sep 1;68(12):1354-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of antisense RNA targeting of ODC and AdoMetDC on the synthesis of polyamine synthesis and cell growth in prostate cancer cells using a prostatic androgen-dependent promoter in adenovirus.
  • PURPOSE: This study was designed to investigate the use of a prostatic androgen-dependent promoter to mediate antisense targeting of ornithine decarboxylase (ODC) and S-adenosylmethionine decarboxylase (AdoMetDC) and its effects on the synthesis of polyamine.
  • We also examined the potential of this construct for prostate cancer therapy.
  • METHODS: pADxsi-PSES-AdoMetDC-ODC-PolyA AV was constructed and used to infect various cancer cell lines, including LNCaP, HT-29, H1299, HepG2.
  • CONCLUSIONS: The pADxsi-PSES-AdoMetDC-ODC-PolyA AV specifically inhibited the expression of ODC and AdoMetDC and the synthesis of polyamine, while it induced p21 expression, resulting in cell growth arrest in the G1 phase in prostate cancer cells but not in other cells.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenosylmethionine Decarboxylase / metabolism. Cell Proliferation / drug effects. Ornithine Decarboxylase / metabolism. Polyamines / metabolism. Prostatic Neoplasms / metabolism. RNA, Antisense / pharmacology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18548481.001).
  • [ISSN] 1097-0045
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Polyamines; 0 / RNA, Antisense; 147336-22-9 / Green Fluorescent Proteins; EC 4.1.1.17 / Ornithine Decarboxylase; EC 4.1.1.50 / Adenosylmethionine Decarboxylase
  •  go-up   go-down


54. Goodwin AC, Jadallah S, Toubaji A, Lecksell K, Hicks JL, Kowalski J, Bova GS, De Marzo AM, Netto GJ, Casero RA Jr: Increased spermine oxidase expression in human prostate cancer and prostatic intraepithelial neoplasia tissues. Prostate; 2008 May 15;68(7):766-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased spermine oxidase expression in human prostate cancer and prostatic intraepithelial neoplasia tissues.
  • BACKGROUND: Inflammation has been strongly implicated in prostate carcinogenesis, but the precise molecular mechanisms linking inflammation and carcinogenic DNA damage are not known.
  • Induction of the polyamine catabolic enzyme, spermine oxidase (SMO) has been linked to increased reactive oxygen species (ROS) and DNA damage in human gastric and lung epithelial cells and suggest direct mechanistic links between inflammation, SMO activity, ROS production, and epithelial carcinogenesis that are likely relevant in prostate cancer.
  • METHODS: Tissue microarrays consisting of matched normal and diseased specimens from patients diagnosed with prostate cancer, prostatic intraepithelial neoplasia (PIN), or proliferative inflammatory atrophy (PIA), as well as unaffected individuals, were stained for SMO expression and analyzed using image analysis techniques and TMAJ software tools.
  • RESULTS: Average SMO staining was significantly higher in prostate cancer and PIN tissues compared to patient-matched benign tissues.
  • Benign tissues from prostate cancer, PIN, and PIA patients also exhibited significantly higher mean SMO expression versus tissues from prostate disease-free patients.
  • CONCLUSIONS: Tissues from patients diagnosed with prostate cancer and PIN exhibit, on average, locally increased SMO expression in regions of prostatic disease and higher overall SMO expression in prostatic epithelial cells compared to healthy individuals.
  • Further studies are warranted to directly examine the role of SMO-produced ROS in prostate carcinogenesis.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • [Cites] Cancer Res. 2001 Jul 15;61(14):5370-3 [11454677.001]
  • [Cites] Urol Oncol. 2007 Sep-Oct;25(5):398-400 [17826659.001]
  • [Cites] Biochem J. 2002 Nov 1;367(Pt 3):665-75 [12141946.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Biochem J. 2003 Feb 15;370(Pt 1):19-28 [12477380.001]
  • [Cites] Cancer Chemother Pharmacol. 2003 Nov;52(5):383-90 [12827295.001]
  • [Cites] J Urol. 2004 Feb;171(2 Pt 2):S36-40 [14713751.001]
  • [Cites] J Cell Biochem. 2004 Feb 15;91(3):540-52 [14755684.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):962-8 [14871826.001]
  • [Cites] Prostate. 2004 Nov 1;61(3):215-27 [15368473.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):781-92 [15510159.001]
  • [Cites] Adv Enzyme Regul. 1987;26:91-105 [3118650.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] J Urol. 2004 Nov;172(5 Pt 2):S6-11; discussion S11-2 [15535435.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8521-5 [15574757.001]
  • [Cites] Eur Urol. 2005 Sep;48(3):379-85 [15961218.001]
  • [Cites] J Biochem. 2006 Jan;139(1):17-25 [16428315.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11125-30 [17145855.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):256-69 [17384581.001]
  • [Cites] Nat Clin Pract Urol. 2007 Jun;4(6):321-32 [17551536.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):8043-50 [17804715.001]
  • [Cites] Cancer Res. 2001 Dec 15;61(24):8617-23 [11751373.001]
  • (PMID = 18302221.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA098454-08; United States / NCI NIH HHS / CA / R01 CA098454; United States / NCI NIH HHS / CA / CA098454; United States / NCI NIH HHS / CA / R01 CA098454-08
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.5.- / Oxidoreductases Acting on CH-NH Group Donors; EC 1.5.3.- / polyamine oxidase
  • [Other-IDs] NLM/ NIHMS281840; NLM/ PMC3065872
  •  go-up   go-down


55. Hainsworth JD, Meluch AA, Spigel DR, Barton J Jr, Simons L, Meng C, Gould B, Greco FA: Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trial. Clin Genitourin Cancer; 2007 Mar;5(4):278-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trial.
  • BACKGROUND: Docetaxel is currently the standard first-line treatment in patients with hormone-refractory prostate cancer (HRPC).
  • Bortezomib, the first proteasome inhibitor in clinical use, demonstrated activity against prostate cancer in phase I trials.
  • All patients had metastatic adenocarcinoma of the prostate that had progressed on hormonal therapy.
  • Fifteen patients (25%; 95% confidence interval, 15%-38%) had a > 50% decrease in serum prostate-specific antigen level with treatment; the median response duration was 8 months.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / administration & dosage. Boronic Acids / administration & dosage. Prostatic Neoplasms / drug therapy. Pyrazines / administration & dosage. Taxoids / administration & dosage

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17553208.001).
  • [ISSN] 1558-7673
  • [Journal-full-title] Clinical genitourinary cancer
  • [ISO-abbreviation] Clin Genitourin Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgens; 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Pyrazines; 0 / Taxoids; 15H5577CQD / docetaxel; 69G8BD63PP / Bortezomib
  •  go-up   go-down


56. Shrivastava V, Christensen R, Poggi MM: Prostate cancer metastatic to the external auditory canals. Clin Genitourin Cancer; 2007 Jun;5(5):341-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate cancer metastatic to the external auditory canals.
  • A 58-year-old white man with prostate-specific antigen (PSA) level of 6 ng/mL, a Gleason score of 6 (3+3), and T2a adenocarcinoma of the prostate underwent prostatectomy.
  • Six months later, he presented with bilateral hearing loss and was found to have pathologic and radiographic evidence of metastatic prostate cancer to the external auditory canals.
  • [MeSH-major] Adenocarcinoma / secondary. Ear Canal / pathology. Ear Neoplasms / secondary. Prostatic Neoplasms / pathology
  • [MeSH-minor] Fatal Outcome. Humans. Male. Middle Aged. Prostate-Specific Antigen / blood. Prostatectomy


57. Jamal K, Challacombe B, Elhage O, Popert R, Kirby R, Dasgupta P: Successful salvage robotic-assisted radical prostatectomy after external beam radiotherapy failure. Urology; 2008 Dec;72(6):1356-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 50-year-old man initially underwent combined external beam radiotherapy and hormonal treatment for Stage T2a prostate adenocarcinoma.
  • The prostate-specific antigen level was 10.5 ng/mL, and the Gleason score was 3+3.
  • His prostate-specific antigen at 3 months was <0.03 ng/mL, and he was continent.
  • Salvage robotic-assisted radical prostatectomy is a safe and technically feasible salvage treatment for prostate cancer for which primary radiotherapy has failed.
  • [MeSH-major] Prostatectomy / methods. Prostatic Neoplasms / radiotherapy. Prostatic Neoplasms / surgery. Radiotherapy / methods. Robotics
  • [MeSH-minor] Humans. Male. Middle Aged. Prostate-Specific Antigen / blood. Salvage Therapy. Treatment Outcome. Urologic Surgical Procedures / methods

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18533232.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


58. Hiros M, Spahović H, Selimović M, Sadović S: Incidental prostate cancer in patients undergoing radical cystoprostatectomy for bladder cancer. Bosn J Basic Med Sci; 2008 May;8(2):147-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidental prostate cancer in patients undergoing radical cystoprostatectomy for bladder cancer.
  • The objective of this work is to verify the incidence of incidental prostate adenocarcinoma in patients who underwent radical cystoprostatectomy for invasive bladder carcinoma.
  • We have retrospectively reviewed patients who underwent radical cystoprostatectomy for infiltrative bladder tumors in period between 2003 and 2007 year, 94 men with bladder cancer underwent radical cystoprostatectomy at Urology Clinic-University of Sarajevo Clinics Centre.
  • We found that 9,57% of cystoprostatectomy specimens in patients with bladder cancer also contained incidental prostate cancer.
  • This result was much lower than overall mean frequency of incidentally detected prostate cancer in other series of cystoprostatectomy cases (range, 23%-68%).
  • In conclusion we recommended digital rectal examination (DRE) and prostate-specific antigen (PSA) test as part of the bladder cancer work up and complete removal of the prostate at cystoprostatectomy to prevent residual prostate cancer.
  • [MeSH-major] Cystectomy / methods. Prostatectomy / methods. Prostatic Neoplasms / complications. Prostatic Neoplasms / diagnosis. Urinary Bladder Neoplasms / complications. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Aged. Carcinoma, Transitional Cell / complications. Carcinoma, Transitional Cell / surgery. Digital Rectal Examination. Humans. Incidental Findings. Male. Medical Oncology / methods. Middle Aged. Prostate-Specific Antigen / biosynthesis. Retrospective Studies. Treatment Outcome


59. Walsh PC, DeWeese TL, Eisenberger MA: Clinical practice. Localized prostate cancer. N Engl J Med; 2007 Dec 27;357(26):2696-705
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical practice. Localized prostate cancer.
  • [MeSH-major] Prostate / pathology. Prostatectomy. Prostatic Neoplasms / radiotherapy. Prostatic Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma. Aged. Humans. Male. Practice Guidelines as Topic. Prostate-Specific Antigen / blood

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18160689.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  • [Number-of-references] 43
  •  go-up   go-down


60. Tokunaga M, Yasuda M, Osamura RY, Itoh J, Mukai M, Shima M, Usui Y, Masuda A, Miyakita H, Terachi T: Association of neuroendocrine differentiation with neoadjuvant hormone therapy effects in prostatic cancer. Oncol Rep; 2005 Jun;13(6):1081-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of neuroendocrine differentiation with neoadjuvant hormone therapy effects in prostatic cancer.
  • Histological therapeutic effects of neoadjuvant hormone therapy (NHT) in prostatic cancer were examined, focusing on the association with neuroendocrine differentiation (NED), using 69 radical prostatectomy cases.
  • NED cells in the cancer were semi-quantified into 4 grades (negative, 1+, 2+, and 3+) by immunohistochemical staining of chromogranin A (CgA).
  • In conclusion, although it seems difficult to predict the therapeutic effects of NHT using the biopsy specimens of prostatic cancer, we believe that NED is negatively associated with histological response of prostatic cancer to NHT.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Cell Differentiation. Neoadjuvant Therapy. Prostatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15870925.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0 / Chromogranin A; 0 / Chromogranins
  •  go-up   go-down


61. Pollack A, Horwitz EM: Is 6 months of androgen suppression therapy plus radiotherapy of benefit in patients with localized prostate cancer? Nat Clin Pract Oncol; 2005 Jan;2(1):12-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is 6 months of androgen suppression therapy plus radiotherapy of benefit in patients with localized prostate cancer?
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antineoplastic Agents, Hormonal / administration & dosage. Antineoplastic Agents, Hormonal / therapeutic use. Goserelin / administration & dosage. Goserelin / therapeutic use. Leuprolide / administration & dosage. Leuprolide / therapeutic use. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. LEUPROLIDE .
  • Hazardous Substances Data Bank. GOSERELIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16264846.001).
  • [ISSN] 1743-4254
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0F65R8P09N / Goserelin; EFY6W0M8TG / Leuprolide
  •  go-up   go-down


62. Tong GX, Weeden EM, Hamele-Bena D, Huan Y, Unger P, Memeo L, O'Toole K: Expression of PAX8 in nephrogenic adenoma and clear cell adenocarcinoma of the lower urinary tract: evidence of related histogenesis? Am J Surg Pathol; 2008 Sep;32(9):1380-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of PAX8 in nephrogenic adenoma and clear cell adenocarcinoma of the lower urinary tract: evidence of related histogenesis?
  • We report here that PAX8 was detected in all nephrogenic adenomas (N=35) and clear cell adenocarcinoma of the lower urinary tract (N=7), but not in prostate adenocarcinoma (N=100), adenocarcinoma (N=9), squamous cell carcinoma (N=5), or urothelial carcinoma (N=48) of the urinary bladder and its variants.
  • PAX8 was neither detected in normal urothelium of the urinary bladder nor in prostate glands and stroma.
  • Expression of PAX8 or PAX2 in both nephrogenic adenoma and clear cell adenocarcinoma of the lower urinary tract may indicate a possible related tissue origin for these 2 lesions; both may be derived from proliferating renal tubular cells in the urinary tract.
  • In addition, detection of PAX8 or PAX2 in clear cell adenocarcinoma of the lower urinary tract is helpful in differentiating it from urothelial carcinoma and its variants and adenocarcinomas of the urinary bladder or of the prostate.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Adenoma / metabolism. Biomarkers, Tumor / analysis. Paired Box Transcription Factors / biosynthesis. Urologic Neoplasms / metabolism

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18670350.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / PAX2 Transcription Factor; 0 / PAX2 protein, human; 0 / PAX8 protein, human; 0 / Paired Box Transcription Factors
  •  go-up   go-down


63. Canene-Adams K, Lindshield BL, Wang S, Jeffery EH, Clinton SK, Erdman JW Jr: Combinations of tomato and broccoli enhance antitumor activity in dunning r3327-h prostate adenocarcinomas. Cancer Res; 2007 Jan 15;67(2):836-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combinations of tomato and broccoli enhance antitumor activity in dunning r3327-h prostate adenocarcinomas.
  • The consumption of diets containing 5 to 10 servings of fruits and vegetables daily is the foundation of public health recommendations for cancer prevention, yet this concept has not been tested in experimental models of prostate cancer.
  • We evaluated combinations of tomato and broccoli in the Dunning R3327-H prostate adenocarcinoma model.
  • Castration reduced prostate weights, tumor areas, and tumor weight (62%, P<0.001), whereas finasteride reduced prostate weights (P<0.0001), but had no effect on tumor area or weight.
  • [MeSH-major] Adenocarcinoma / prevention & control. Brassica. Diet. Lycopersicon esculentum. Prostatic Neoplasms / prevention & control

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17213256.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 36-88-4 / Carotenoids; SB0N2N0WV6 / lycopene
  •  go-up   go-down


64. Sawada A, Segawa T, Nakanishi S, Kinoshita H, Yamamoto S, Kamoto T, Ogawa O: [Prostate cancer with penile metastasis: a case report]. Hinyokika Kiyo; 2005 Nov;51(11):771-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prostate cancer with penile metastasis: a case report].
  • Laboratory examination revealed elevated serum prostate-specific antigen (PSA) and CA19-9.
  • Pathological examinations on prostate and penile biopsy specimens revealed prostate adenocarcinoma with penile metastasis.
  • The patient was diagnosed as having prostate cancer stage D2 (T4N1M1) with bone, lymph node and penile metastases.
  • [MeSH-major] Adenocarcinoma / secondary. Penile Neoplasms / secondary. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. CA-19-9 Antigen / blood. Carboplatin / administration & dosage. Combined Modality Therapy. Estramustine / administration & dosage. Humans. Male. Orchiectomy. Paclitaxel / administration & dosage. Prostate-Specific Antigen / blood

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16363713.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 35LT29625A / Estramustine; BG3F62OND5 / Carboplatin; EC 3.4.21.77 / Prostate-Specific Antigen; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


65. Nanda A, D'Amico AV: Hormonal therapy and radiation for prostate cancer: is it safe? Expert Rev Anticancer Ther; 2010 Jul;10(7):979-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hormonal therapy and radiation for prostate cancer: is it safe?
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / etiology. Antineoplastic Agents, Hormonal / adverse effects. Brachytherapy. Prostatic Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20645684.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Editorial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal
  •  go-up   go-down


66. Zerbib M, Bouchot O: [Prostate cancer incidence on specimen of cystoprostatectomy for infiltrative bladder cancer]. Prog Urol; 2005 Dec;15(6 Suppl 1):1262-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prostate cancer incidence on specimen of cystoprostatectomy for infiltrative bladder cancer].
  • [Transliterated title] Découverte fortuite d'un cancer de prostate sur la pièce de cystoprostatectomie totale pour tumeur infiltrante de vessie.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Carcinoma in Situ / pathology. Carcinoma in Situ / surgery. Cystectomy. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / surgery. Prostatectomy. Prostatic Neoplasms / pathology. Prostatic Neoplasms / surgery. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery


67. Chianakwalam CI, McCahy P, Griffiths NJ: A case of male breast cancer in association with bicalutamide-induced gynaecomastia. Breast; 2005 Apr;14(2):163-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of male breast cancer in association with bicalutamide-induced gynaecomastia.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Aged. Humans. Male. Nitriles. Prostatic Neoplasms / drug therapy. Tosyl Compounds

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Breast Cancer, Male.
  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • Hazardous Substances Data Bank. BICALUTAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15767188.001).
  • [ISSN] 0960-9776
  • [Journal-full-title] Breast (Edinburgh, Scotland)
  • [ISO-abbreviation] Breast
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Anilides; 0 / Nitriles; 0 / Tosyl Compounds; A0Z3NAU9DP / bicalutamide
  •  go-up   go-down


68. Herawi M, Parwani AV, Irie J, Epstein JI: Small glandular proliferations on needle biopsies: most common benign mimickers of prostatic adenocarcinoma sent in for expert second opinion. Am J Surg Pathol; 2005 Jul;29(7):874-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small glandular proliferations on needle biopsies: most common benign mimickers of prostatic adenocarcinoma sent in for expert second opinion.
  • The current study aimed to determine the incidence of various benign mimickers of prostatic adenocarcinoma most commonly encountered in a busy consultation practice.
  • All prostate needle biopsies from the consult service of one of the authors were prospectively evaluated over a 7-month period.
  • Crowded benign glands, insufficiently crowded or numerous to warrant a diagnosis of adenosis, was the second most common mimicker (146 of 567; 25.7%).
  • In the past, complete atrophy, adenosis, seminal vesicle, and granulomatous prostatitis were considered common mimickers of prostate cancer on prostatic needle biopsies.
  • [MeSH-major] Adenocarcinoma / pathology. Biopsy, Needle. Prostate / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Atrophy / metabolism. Atrophy / pathology. Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Prostatic Hyperplasia / metabolism. Prostatic Hyperplasia / pathology. Referral and Consultation

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15958851.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


69. Baydar DE, Himmetoglu C: Test and Teach. Abnormal glands in the uterine cervix Part 1. Diagnosis: Ectopic prostate tissue in the uterine cervix. Pathology; 2008 Jun;40(4):407-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Test and Teach. Abnormal glands in the uterine cervix Part 1. Diagnosis: Ectopic prostate tissue in the uterine cervix.
  • [MeSH-major] Cervix Uteri / pathology. Choristoma / pathology. Prostate. Uterine Cervical Diseases / pathology
  • [MeSH-minor] Acid Phosphatase. Adenocarcinoma / diagnosis. Carcinoma in Situ / diagnosis. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Basal Cell / diagnosis. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Prostate-Specific Antigen / metabolism. Protein Tyrosine Phosphatases / metabolism. Uterine Cervical Neoplasms / diagnosis


70. Frota AC, Bakalian S, Grégoire FJ, Fernandes BF, Burnier MN Jr: Pseudomelanoma in a patient with prostate adenocarcinoma. Can J Ophthalmol; 2007 Apr;42(2):305-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudomelanoma in a patient with prostate adenocarcinoma.
  • CASE REPORT: A 72-year-old man referred for evaluation of a uveal melanoma was revealed with primary prostate adenocarcinoma metastatic to the choroid.
  • COMMENTS: Differential diagnosis of choroidal tumours may be difficult but should include both uveal melanoma and metastatic carcinoma to the uvea.
  • Proper diagnosis and treatment is of great relevance for increasing survival rates.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17392857.001).
  • [ISSN] 0008-4182
  • [Journal-full-title] Canadian journal of ophthalmology. Journal canadien d'ophtalmologie
  • [ISO-abbreviation] Can. J. Ophthalmol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


71. Hepel JT, MacAusland SG, Long JP, Wazer DE, DiPetrillo T: Intensity-modulated radiotherapy of the prostate after cryotherapy: initial experience. Urology; 2008 Dec;72(6):1310-4; discussion 1314
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity-modulated radiotherapy of the prostate after cryotherapy: initial experience.
  • OBJECTIVES: To analyze results of intensity-modulated radiotherapy after cryotherapy ablation for adenocarcinoma of the prostate.
  • METHODS: Patients were either treated adjuvantly after targeted cryotherapy or treated for salvage after local failure of standard whole-prostate cryotherapy.
  • Prostate-specific antigen (PSA) failure was defined according to the Radiation Therapy Oncology Group-American Society for Therapeutic Radiology and Oncology 2006 consensus definition.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Cryotherapy / methods. Prostatic Neoplasms / pathology. Prostatic Neoplasms / radiotherapy. Radiotherapy, Intensity-Modulated / methods
  • [MeSH-minor] Aged. Biopsy. Humans. Male. Middle Aged. Prostate-Specific Antigen / biosynthesis. Risk. Salvage Therapy / methods. Temperature. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18502482.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


72. Schaue D, Koya RC, Liao YP, Ribas A, McBride WH: Immune rejection in a humanized model of murine prostate cancer. Anticancer Res; 2010 Feb;30(2):409-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immune rejection in a humanized model of murine prostate cancer.
  • BACKGROUND/AIM: We attempted to develop a humanized mouse model for prostate cancer to study immune recognition and responses to human prostate-tumor antigens in mice.
  • MATERIALS AND METHODS: Our study was based on cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) tumors.
  • [MeSH-major] Adenocarcinoma / immunology. Antigens, Neoplasm / immunology. Disease Models, Animal. HLA-A2 Antigen / immunology. Immune Tolerance / immunology. Prostatic Neoplasms / immunology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20332447.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Epitopes; 0 / HLA-A2 Antigen
  •  go-up   go-down


73. Lledó García E, Jara Rascón J, Díez Cordero JM, Subirá Ríos D, Alvarado A, Fernández de Lomana FA, Hernández Fernández C: [Localized prostate cancer treatment in renal transplant patient with high intensity focalized ultrasound (HIFU)]. Actas Urol Esp; 2005 Jan;29(1):70-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Localized prostate cancer treatment in renal transplant patient with high intensity focalized ultrasound (HIFU)].
  • [Transliterated title] Tratamiento de adenocarcinoma prostático localizado en paciente con trasplante renal mediante Ultrasonido de Alta Intensidad.
  • We report a 62 years old kidney transplant (KT) patient who was diagnosed of localized prostatic cancer (PC) after 6 years of the implant.
  • Transrectal prostatic High Intensity Focused Ultrasound (HIFU) was applied.
  • [MeSH-major] Adenocarcinoma / therapy. Kidney Transplantation. Prostatic Neoplasms / therapy. Ultrasound, High-Intensity Focused, Transrectal / methods
  • [MeSH-minor] Biopsy, Needle. Humans. Male. Middle Aged. Postoperative Period. Prostate / diagnostic imaging. Prostate / pathology. Transurethral Resection of Prostate. Treatment Outcome. Ultrasonography


74. Roberts-Thomson R, Rosenthal MA, Gonzales M, Drummond K: Brain metastases in hormone refractory prostate cancer: a changing natural history? Intern Med J; 2009 Mar;39(3):205-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain metastases in hormone refractory prostate cancer: a changing natural history?
  • [MeSH-major] Adenocarcinoma / pathology. Brain Neoplasms / secondary. Infratentorial Neoplasms / secondary. Neoplasms, Hormone-Dependent / pathology. Prostatic Neoplasms / pathology


75. Rubin MA, Montie JE: Benign positive margins after radical prostatectomy means a poor prognosis--con. Urology; 2005 Feb;65(2):221-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / pathology. Neoplasm Recurrence, Local / diagnosis. Neoplasms, Second Primary / diagnosis. Prostate / pathology. Prostate-Specific Antigen / blood. Prostatectomy / methods. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Urology. 2005 Feb;65(2):218-20 [15708025.001]
  • (PMID = 15708026.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Comment; Editorial; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Number-of-references] 8
  •  go-up   go-down


76. Jin RJ, Lho Y, Wang Y, Ao M, Revelo MP, Hayward SW, Wills ML, Logan SK, Zhang P, Matusik RJ: Down-regulation of p57Kip2 induces prostate cancer in the mouse. Cancer Res; 2008 May 15;68(10):3601-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Down-regulation of p57Kip2 induces prostate cancer in the mouse.
  • However, little is known about the role of p57(Kip2) in tumorigenesis and cancer progression.
  • Here, we show that the expression of p57(Kip2) is significantly decreased in human prostate cancer, and the overexpression of p57(Kip2) in prostate cancer cells significantly suppressed cell proliferation and reduced invasive ability.
  • In addition, overexpression of p57(Kip2) in LNCaP cells inhibited tumor formation in nude mice, resulting in well-differentiated squamous tumors rather than adenocarcinoma.
  • Furthermore, the prostates of p57(Kip2) knockout mice developed prostatic intraepithelial neoplasia and adenocarcinoma.
  • Remarkably, this mouse prostate cancer is pathologically identical to human prostate adenocarcinoma.
  • Therefore, these results strongly suggest that p57(Kip2) is an important gene in prostate cancer tumorigenesis, and the p57(Kip2) pathway may be a potential target for prostate cancer prevention and therapy.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p57 / biosynthesis. Down-Regulation. Gene Expression Regulation, Neoplastic. Prostatic Neoplasms / metabolism

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18483241.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA116097; United States / NCI NIH HHS / CA / R01-CA76142
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cdkn1c protein, mouse; 0 / Cyclin D; 0 / Cyclin-Dependent Kinase Inhibitor p57; 0 / Cyclins; 0 / Retinoblastoma Protein; EC 2.7.11.22 / Cdk2 protein, mouse; EC 2.7.11.22 / Cdk4 protein, mouse; EC 2.7.11.22 / Cyclin-Dependent Kinase 2; EC 2.7.11.22 / Cyclin-Dependent Kinase 4
  •  go-up   go-down


77. Tunc M, Sanli O, Kandirali E, Tefekli A, Oktar T, Esen T, Acar O, Uysal V: Should high-grade prostatic intraepithelial neoplasia change our approach to infravesical obstruction? Urol Int; 2005;74(4):332-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Should high-grade prostatic intraepithelial neoplasia change our approach to infravesical obstruction?
  • OBJECTIVES: To investigate whether coexistence of high-grade prostatic intraepithelial neoplasia (HPIN) should change our therapeutic approach to infravesical obstruction.
  • MATERIAL AND METHODS: Of 505 patients who underwent sextant transrectal ultrasonography (TRUS)-guided prostate biopsy, 65 (12.8%) had HPIN and 29 of them underwent prostatectomy (23 transurethral resection of prostate (TURP), 6 open) due to obstructive urinary symptoms.
  • Patients without carcinoma were followed up with semiannual prostate-specific antigen (PSA) and digital rectal examination.
  • The final pathological evaluation of the surgical specimens revealed 2 prostatic adenocarcinomas both in the TURP group.
  • The remaining 27 (93.2%) patients were found to have benign prostatic hyperplasia (BPH) and their serum PSA levels declined from 9.26 +/- 5.91 to 4.59 +/- 2.0 ng/ml 3 months after prostatectomy.
  • [MeSH-major] Adenocarcinoma / surgery. Prostatectomy / methods. Prostatic Intraepithelial Neoplasia / surgery. Prostatic Neoplasms / surgery. Urethral Obstruction / surgery
  • [MeSH-minor] Aged. Biopsy. Humans. Male. Middle Aged. Prostate / pathology. Prostatic Hyperplasia / complications. Prostatic Hyperplasia / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 S. Karger AG, Basel
  • (PMID = 15897699.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


78. Khurshid A, Ahmad Z: Concomitant urothelial carcinoma and prostatic adenocarcinoma. J Coll Physicians Surg Pak; 2007 Nov;17(11):708-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant urothelial carcinoma and prostatic adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18070587.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


79. Shi HY, Wei LX, Zhou ZH, Wen ZL: [Morphologic diagnosis and clinical significance of prostatic atypical small acinar proliferation suspicious but not diagnostic of cancer]. Zhonghua Bing Li Xue Za Zhi; 2006 Nov;35(11):660-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Morphologic diagnosis and clinical significance of prostatic atypical small acinar proliferation suspicious but not diagnostic of cancer].
  • OBJECTIVE: To study the morphologic features and clinical significance of atypical small acinar proliferation (ASAP) suspicious but not diagnostic of cancer in prostatic biopsies.
  • METHODS: The slides of 11 cases of prostatic needle biopsies collected during a two-year period with the diagnosis of ASAP were reviewed.
  • RESULTS: All the 11 ASAP cases were characterized by the presence of a few compacted small acini in the prostatic stroma.
  • CONCLUSIONS: ASAP is a morphologic interpretation closely associated with prostatic adenocarcinoma.
  • The histologic features are suspicious of but not diagnostic of cancer, due to insufficient criteria in terms of acinar number, cytologic or architectural abnormalities.
  • [MeSH-major] Adenocarcinoma / pathology. Prostate / pathology. Prostatic Hyperplasia / pathology. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Biopsy. Diagnosis, Differential. Humans. Male. Middle Aged. Racemases and Epimerases / metabolism

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17374209.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


80. Doyle-Lindrud S: Implications of androgen-deprivation therapy in patients with prostate cancer: A case study. Clin J Oncol Nurs; 2006 Oct;10(5):565-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Implications of androgen-deprivation therapy in patients with prostate cancer: A case study.
  • S.R., a 65-year-old male with a history of prostate cancer, went to a cancer center in 2003.
  • His baseline prostate-specific antigen (PSA) was 44 ng/ml.
  • On physical examination, his prostate was enlarged, and a biopsy in January 2000 revealed adenocarcinoma with a Gleason score of 8.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Hormonal / adverse effects. Leuprolide / adverse effects. Osteoporosis / chemically induced. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Androgen Antagonists / adverse effects. Bone Density Conservation Agents / adverse effects. Combined Modality Therapy. Diphosphonates / adverse effects. Gonadotropin-Releasing Hormone / agonists. Humans. Imidazoles / adverse effects. Jaw Diseases / chemically induced. Male. Orchiectomy. Osteonecrosis / chemically induced. Prostate-Specific Antigen / blood. Radiotherapy, Conformal. Risk Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Osteoporosis.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LEUPROLIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17063610.001).
  • [ISSN] 1092-1095
  • [Journal-full-title] Clinical journal of oncology nursing
  • [ISO-abbreviation] Clin J Oncol Nurs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Antineoplastic Agents, Hormonal; 0 / Bone Density Conservation Agents; 0 / Diphosphonates; 0 / Imidazoles; 33515-09-2 / Gonadotropin-Releasing Hormone; 6XC1PAD3KF / zoledronic acid; EC 3.4.21.77 / Prostate-Specific Antigen; EFY6W0M8TG / Leuprolide
  • [Number-of-references] 10
  •  go-up   go-down


81. Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, Jensen JK, Olesen TK, Schröder FH: The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int; 2008 Dec;102(11):1531-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
  • OBJECTIVE: To evaluate the efficacy and safety of degarelix, a new gonadotrophin-releasing hormone (GnRH) antagonist (blocker), vs leuprolide for achieving and maintaining testosterone suppression in a 1-year phase III trial involving patients with prostate cancer.
  • PATIENTS AND METHODS: In all, 610 patients with adenocarcinoma of the prostate (any stage; median age 72 years; median testosterone 3.93 ng/mL, median prostate-specific antigen, PSA, level 19.0 ng/mL) were randomized and received study treatment.
  • Degarelix represents an effective therapy for inducing and maintaining androgen deprivation for up to 1 year in patients with prostate cancer, and has a different mechanism of action from traditional GnRH agonists.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Gonadotropin-Releasing Hormone / antagonists & inhibitors. Oligopeptides / therapeutic use. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Humans. Leuprolide / therapeutic use. Male. Middle Aged. Prospective Studies. Prostate-Specific Antigen / metabolism. Testosterone / metabolism. Treatment Outcome

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. LEUPROLIDE .
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] BJU Int. 2009 Jan;103(2):145-6 [19278531.001]
  • [CommentIn] Eur Urol. 2009 Jun;55(6):1488-9 [19650242.001]
  • (PMID = 19035858.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Oligopeptides; 0 / acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide; 33515-09-2 / Gonadotropin-Releasing Hormone; 3XMK78S47O / Testosterone; EC 3.4.21.77 / Prostate-Specific Antigen; EFY6W0M8TG / Leuprolide
  •  go-up   go-down


82. Hameed O, Humphrey PA: Immunohistochemistry in diagnostic surgical pathology of the prostate. Semin Diagn Pathol; 2005 Feb;22(1):88-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemistry in diagnostic surgical pathology of the prostate.
  • Immunohistochemistry (IHC) can play an important role in diagnostic surgical pathology of the prostate.
  • Basal cell markers, such as the 34betaE12 antibody and antibodies directed against cytokeratin 5 and 6 or p63, are very useful for demonstration of basal cells as their presence argues against a diagnosis of invasive prostatic carcinoma (PC).
  • However, several benign mimickers of PC, including atrophy, atypical adenomatous hyperplasia (AAH), nephrogenic adenoma, and mesonephric hyperplasia, can stain negatively with these markers, and thus, a negative basal cell marker immunostain alone does not exclude a diagnosis of benignancy.
  • Alpha-methylacyl-coenzyme-A racemase (AMACR) is a sensitive marker of PC (except for a few uncommon variants: atrophic, foamy gland, and pseudohyperplastic variants), and its detection by immunohistochemical staining in atypical prostatic lesions can be very useful in confirming an impression of adenocarcinoma.
  • AMACR expression can also be identified in high grade prostatic intraepithelial neoplasia (PIN), prostatic atrophy, AAH, and benign prostatic glands, and accordingly, a diagnosis of PC should not be based solely on a positive AMACR immunostain, especially when the luminal staining is weak and/or noncircumferential.
  • Prostate specific antigen (PSA) and prostate specific acid phosphatase (PSAP) are both quite sensitive and fairly specific markers of PC (there are a few nonprostatic tumors that can express one or both), and are both very helpful in establishing or confirming the diagnosis of PC when the differential diagnosis includes other tumors that can involve the prostate such as urinary bladder urothelial carcinoma.
  • 34betaE12, p63, thrombomodulin, and uroplakin III are additional urothelial associated markers useful in this differential diagnosis.
  • CDX2 and villin are useful markers to diagnostically separate colonic adenocarcinoma from PC.
  • PSA and PSAP immunohistochemical stains are valuable in confirming metastatic carcinoma as being of prostatic origin and should always be utilized in the diagnostic evaluation of metastatic adenocarcinoma of unknown primary origin in males.
  • [MeSH-major] Carcinoma / diagnosis. Immunohistochemistry. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / pathology. Diagnosis, Differential. Humans. Leukemia / diagnosis. Lymphoma / diagnosis. Male. Neoplasm Metastasis. Sarcoma / diagnosis. Sensitivity and Specificity. Urinary Bladder Neoplasms / diagnosis


83. Hermani A, Hess J, De Servi B, Medunjanin S, Grobholz R, Trojan L, Angel P, Mayer D: Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer. Clin Cancer Res; 2005 Jul 15;11(14):5146-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer.
  • We examined the expression of two members of this family, S100A8 and S100A9, together with the S100 receptor RAGE (receptor for advanced glycation end products) in human prostate adenocarcinomas and in prostatic intraepithelial neoplasia.
  • EXPERIMENTAL DESIGN: Tissue specimens of 75 patients with organ-confined prostate cancer of different grades were analyzed by immunohistochemistry for expression of S100A8, S100A9, and RAGE.
  • An ELISA was applied to determine serum concentrations of S100A9 in cancer patients compared with healthy controls or to patients with benign prostatic hyperplasia (BPH).
  • RESULTS: S100A8, S100A9, and RAGE were up-regulated in prostatic intraepithelial neoplasia and preferentially in high-grade adenocarcinomas, whereas benign tissue was negative or showed weak expression of the proteins.
  • Frequently, a gradient within the tumor tissue with an increased expression toward the invaded stroma of the prostate was observed.
  • S100A9 serum levels were significantly elevated in cancer patients compared with BPH patients or healthy individuals.
  • CONCLUSION: Our data suggest that enhanced expression of S100A8, S100A9, and RAGE is an early event in prostate tumorigenesis and may contribute to development and progression or extension of prostate carcinomas.
  • Furthermore, S100A9 in serum may serve as useful marker to discriminate between prostate cancer and BPH.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / biosynthesis. Calgranulin A / biosynthesis. Calgranulin B / biosynthesis. Prostatic Intraepithelial Neoplasia / diagnosis. Prostatic Neoplasms / diagnosis. Receptors, Immunologic / biosynthesis
  • [MeSH-minor] Adult. Advanced Glycosylation End Product-Specific Receptor. Aged. Aged, 80 and over. Case-Control Studies. Diagnosis, Differential. Disease Progression. Enzyme-Linked Immunosorbent Assay. Gene Expression Profiling. Glycosylation End Products, Advanced. Humans. Immunohistochemistry. In Situ Hybridization. Male. Middle Aged. Up-Regulation

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16033829.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Advanced Glycosylation End Product-Specific Receptor; 0 / Biomarkers, Tumor; 0 / Calgranulin A; 0 / Calgranulin B; 0 / Glycosylation End Products, Advanced; 0 / Receptors, Immunologic
  •  go-up   go-down


84. Mooney CJ, Dunphy EJ, Stone B, McNeel DG: Identification of autoantibodies elicited in a patient with prostate cancer presenting as dermatomyositis. Int J Urol; 2006 Mar;13(3):211-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of autoantibodies elicited in a patient with prostate cancer presenting as dermatomyositis.
  • Dermatomyositis has also frequently been associated with malignancy, typically heralding the diagnosis of ovarian, lung, gastric, or colorectal cancer.
  • We report an unusual case of prostate adenocarcinoma preceded by a diagnosis of dermatomyositis.
  • We hypothesized that in this particular patient, proteins produced by the neoplastic prostatic tissue, which might be normally expressed in muscle tissue, were immunologically recognized as autoantigens.
  • METHODS: Serum from this patient was used to screen a cDNA lambda phage expression library from normal prostate tissue for prostate protein-specific IgG.
  • IgG specific for these proteins were not specifically recognized in sera from other patients with prostate cancer compared with male control blood donors, and were not specifically recognized in a small panel of sera from patients with breast or ovarian cancer and dermatomyositis.
  • CONCLUSIONS: Our results demonstrate that this patient with prostate cancer presenting as dermatomyositis had autoantibodies to specific proteins, possibly associated with his autoimmune myopathy.
  • Moreover, given this patient's history and the multiple treatment options for prostate cancer, the identification of dermatomyositis in men should prompt an evaluation to exclude a concurrent diagnosis of prostate cancer.
  • [MeSH-major] Adenocarcinoma / immunology. Antibodies, Anti-Idiotypic / immunology. Dermatomyositis / diagnosis. Immunoglobulin G / immunology. Prostatic Neoplasms / immunology
  • [MeSH-minor] Aged. Diagnosis, Differential. Follow-Up Studies. Humans. Male. Prostate-Specific Antigen / blood

  • Genetic Alliance. consumer health - Dermatomyositis.
  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16643611.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / K23 RR16489
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antibodies, Anti-Idiotypic; 0 / Immunoglobulin G; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


85. Hadzi-Dokic J, Acimovic M, Dzamic Z, Pejcic T, Radosavljevic T, Basic D, Colovic V, Petrovic M, Obradovic G: Radical retropubic prostatectomy--results in 127 surgically treated patients. Acta Chir Iugosl; 2005;52(4):55-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Radical prostatectomy represents an optimal therapeutic method in treatment of the localized prostatic carcinoma.
  • All the patients were preoperatively diagnosed with the localized prostatic carcinoma.
  • [MeSH-major] Adenocarcinoma / surgery. Prostatectomy. Prostatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16673596.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


86. Li HW, Leung SW, Chan CS, Yu MM, Wong YF: Expression of maspin in endometrioid adenocarcinoma of endometrium. Oncol Rep; 2007 Feb;17(2):393-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of maspin in endometrioid adenocarcinoma of endometrium.
  • Underexpression of maspin has been reported in breast and prostatic cancers, but in some cancers such as ovarian, colorectal and pancreatic carcinoma, it was found to be up-regulated.
  • This study aimed at demonstrating the expression of maspin in human endometrial tissue and searching for any altered expression in endometrioid adenocarcinoma of the endometrium compared to normal endometrium.
  • The expression level of the maspin gene was studied using reverse transcriptase-polymerase chain reaction (RT-PCR) performed on RNA extracted from 34 endometrial cancer samples (including 24 with FIGO stage I disease and 10 with FIGO stage III disease) and 28 normal endometrium in proliferative or secretory phases.
  • Immunohistochemical staining was also performed on 10 cases of endometrial cancer (6 FIGO stage I cases and 4 FIGO stage III cases) as well as 15 normal endometrium.
  • Semi-quantitative RT-PCR revealed that the expression of maspin was significantly up-regulated in both stage I (p<0.01) and stage III (p<0.01) endometrial cancer compared with normal endometrium.
  • However, no significant difference in maspin expression was demonstrated between stage I and stage III endometrial cancer.
  • In 60% of the cancer cases, cytoplasmic staining was also evident.
  • Our results suggested that there is up-regulated expression of maspin in endometrioid endometrial adenocarcinoma.
  • Cytoplasmic immuno-expression of maspin is common in endometrial cancer.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17203179.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA Primers; 0 / SERPIN-B5; 0 / Serpins
  •  go-up   go-down


87. Saito T, Kitamura Y, Komatsubara S: [Prognosis of prostate cancer with elevated prostatic acid phosphatase]. Hinyokika Kiyo; 2006 Mar;52(3):177-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognosis of prostate cancer with elevated prostatic acid phosphatase].
  • To evaluate the significance of prostatic acid phosphatase (PAP), we analyzed 1,029 prostate cancer patients who were treated at the Niigata Cancer Center.
  • We classified clinically localized prostate cancer with elevated PAP as stage DO.
  • The significance of PAP in the staging of prostate cancer is limited.
  • [MeSH-major] Adenocarcinoma / mortality. Prostatic Neoplasms / mortality. Protein Tyrosine Phosphatases / blood

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16617869.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] EC 3.1.3.2 / Acid Phosphatase; EC 3.1.3.2 / prostatic acid phosphatase; EC 3.1.3.48 / Protein Tyrosine Phosphatases
  •  go-up   go-down


88. Kim KM, Song JJ, An JY, Kwon YT, Lee YJ: Pretreatment of acetylsalicylic acid promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by down-regulating BCL-2 gene expression. J Biol Chem; 2005 Dec 9;280(49):41047-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been shown to be selective in the induction of apoptosis in cancer cells with minimal toxicity to normal tissues.
  • Thus, TRAIL-resistant cancer cells must be sensitized first to become responsive to TRAIL.
  • In this study, we observed that pretreatment by acetylsalicylic acid (ASA) augmented TRAIL-induced apoptotic death in human prostate adenocarcinoma LNCaP and human colorectal carcinoma CX-1 cells.
  • [MeSH-minor] Blotting, Western. Caspase 3. Caspase 8. Caspase 9. Caspases / metabolism. Cell Line, Tumor. Colonic Neoplasms. Electrophoretic Mobility Shift Assay. Enzyme Activation / drug effects. Enzyme Inhibitors / pharmacology. Flow Cytometry. Humans. I-kappa B Kinase / antagonists & inhibitors. I-kappa B Proteins / metabolism. In Situ Nick-End Labeling. Male. Mitochondria / drug effects. NF-kappa B / antagonists & inhibitors. Phosphorylation. Poly(ADP-ribose) Polymerases / metabolism. Prostatic Neoplasms. Recombinant Proteins. Reverse Transcriptase Polymerase Chain Reaction. TNF-Related Apoptosis-Inducing Ligand. Transfection

  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16199534.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA95191; United States / NCI NIH HHS / CA / CA96989
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Enzyme Inhibitors; 0 / I-kappa B Proteins; 0 / Membrane Glycoproteins; 0 / NF-kappa B; 0 / Recombinant Proteins; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human; 0 / Tumor Necrosis Factor-alpha; 139874-52-5 / NF-kappaB inhibitor alpha; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 2.7.11.10 / I-kappa B Kinase; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / CASP8 protein, human; EC 3.4.22.- / CASP9 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 8; EC 3.4.22.- / Caspase 9; EC 3.4.22.- / Caspases; R16CO5Y76E / Aspirin
  •  go-up   go-down


89. Wikström P, Lindahl C, Bergh A: Characterization of the autochthonous transgenic adenocarcinoma of the mouse prostate (TRAMP) as a model to study effects of castration therapy. Prostate; 2005 Feb 1;62(2):148-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of the autochthonous transgenic adenocarcinoma of the mouse prostate (TRAMP) as a model to study effects of castration therapy.
  • BACKGROUND: In order to learn more about short- and long-term effects of castration therapy, relevant model systems for prostate cancer are required.
  • In this study, we examined whether the transgenic adenocarcinoma of the mouse prostate (TRAMP) tumor response to castration in C57BL/6 mice mimics that seen in patients.
  • RESULTS: Cancer developed preferentially in the dorso-lateral prostate lobe.
  • CONCLUSIONS: The C57Bl/6 TRAMP tumor in several ways mimics how prostate cancer in patients responds to castration both in the short and long term, but some differences may also exist.
  • [MeSH-major] Adenocarcinoma / surgery. Disease Models, Animal. Mice, Transgenic. Orchiectomy. Prostatic Neoplasms / surgery
  • [MeSH-minor] Androgens / metabolism. Animals. Antigens, Polyomavirus Transforming / metabolism. Cell Death. Cell Division. Female. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Mice. Mice, Inbred C57BL. Neoplasm Recurrence, Local. Prostate / metabolism. Prostate / pathology. Receptors, Androgen / metabolism. Seminal Vesicles / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley-Liss, Inc.
  • (PMID = 15389804.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgens; 0 / Antigens, Polyomavirus Transforming; 0 / Receptors, Androgen
  •  go-up   go-down


90. Nese N, Kesici G, Lekili M, Isisag A: Urachal urothelial carcinoma diagnosed at a radical prostatectomy operation: a case report. Anal Quant Cytol Histol; 2010 Jun;32(3):174-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prostate specific antigen (PSA) was 5.46 ng/mL.
  • Prostatic adenocarcinoma (PCa) (Gleason score 6) was diagnosed by needle biopsies.
  • After the diagnosis of high grade, muscle invasive UCa with intact mucosa on frozen examination of the dome of bladder wall during the radical prostatectomy operation (RPO), partial cystectomy was performed.
  • Six months after the diagnosis, an undifferentiated tumor was detected in a bladder transurethral resection specimen; thus, chemotherapy was given.

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20701072.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Viani GA, Pellizzon AC, Guimarães FS, Jacinto AA, dos Santos Novaes PE, Salvajoli JV: High dose rate and external beam radiotherapy in locally advanced prostate cancer. Am J Clin Oncol; 2009 Apr;32(2):187-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High dose rate and external beam radiotherapy in locally advanced prostate cancer.
  • PURPOSE: To report the outcomes and toxicity of high dose rate brachytherapy as a boost for localized prostate cancer.
  • MATERIALS AND METHODS: Between 1997 and 2000, the medical records of 131 patients with prostate adenocarcinoma who were treated with external beam radiation therapy and high dose rate brachytherapy, were retrospectively analyzed.
  • Group 1 included 65 patients with Gleason score 7, pretreatment prostate specific antigen (PSA) between 10 and 20 ng/mL, and clinical stage T2b.
  • CONCLUSIONS: External beam radiation therapy and high dose rate brachytherapy for prostate cancer resulted in excellent BC, and overall survival with minimal severe, acute, or late complications.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy. Prostatic Neoplasms / radiotherapy


92. Cotrina Monroy AP, López López A, Ruiz Solis S, Gómez Embuena A: [Incidental finding of a meningioma-en-plaque in a patient with prostate adenocarcinoma]. Rev Esp Med Nucl; 2010 Sep-Oct;29(5):254-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Incidental finding of a meningioma-en-plaque in a patient with prostate adenocarcinoma].
  • [Transliterated title] Hallazgo incidental de un meningioma en placa en un paciente con adenocarcinoma de próstata.
  • We present a case of a large MEP, which was an incidental finding on a scintigraphy study of a patient with prostate adenocarcinoma, this finding being histologically confirmed.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Incidental Findings. Meningeal Neoplasms / radionuclide imaging. Meningioma / radionuclide imaging. Neoplasms, Multiple Primary / radionuclide imaging. Prostatic Neoplasms / radionuclide imaging
  • [MeSH-minor] Aged. Craniocerebral Trauma / radionuclide imaging. Diagnosis, Differential. Diagnostic Errors. Exophthalmos / etiology. Headache / etiology. Humans. Magnetic Resonance Imaging. Male. Osteitis Deformans / radionuclide imaging. Radiopharmaceuticals. Skull Neoplasms / radionuclide imaging. Skull Neoplasms / secondary. Technetium Tc 99m Medronate. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 Elsevier España, S.L. y SEMNIM. All rights reserved.
  • (PMID = 20398966.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; X89XV46R07 / Technetium Tc 99m Medronate
  •  go-up   go-down


93. Tohfe M, Baki SA, Saliba W, Ghandour F, Ashou R, Ghazal G, Bahous J, Chamseddine N: Metastatic prostate adenocarcinoma presenting with pulmonary symptoms: a case report and review of the literature. Cases J; 2008;1(1):316
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic prostate adenocarcinoma presenting with pulmonary symptoms: a case report and review of the literature.
  • INTRODUCTION: Prostate cancer has a high tendency to spread to bone.
  • Few patients with prostate cancer present initially with symptomatic metastatic lung lesions and lymphadenopathy without any other concomitant distant dissemination.
  • Despite the absence of any detectable osseous lesions and with the presence of multiple hilar, mediastinal, para-aortic, and pelvic lymphadenopathy, the patient had a complete work-up in search for the primary adenocarcinoma.
  • His prostate specific antigen was 146 ng/ml and a prostatic biopsy done, revealing an acinar prostatic adenocarcinoma.
  • A tru-cut biopsy of a lung lesion under computed tomography guidance showed a metastatic prostatic adenocarcinoma positive for prostate specific antigen stain.
  • CONCLUSION: This case sheds light on an unusual metastatic pattern of prostatic adenocarcinoma.
  • It also emphasizes the importance of including prostate cancer in the differential diagnosis of men with adenocarcinoma of unknown origin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Urol Oncol. 2006 May-Jun;24(3):216-9 [16678051.001]
  • [Cites] Urol Int. 1998 Oct;61(1):17-21 [9792977.001]
  • [Cites] Cancer. 1995 Jun 1;75(11):2706-9 [7743474.001]
  • [Cites] Hum Pathol. 2000 May;31(5):578-83 [10836297.001]
  • [Cites] Cancer. 1984 Dec 15;54(12):3078-84 [6498785.001]
  • [Cites] Cancer. 1990 Apr 15;65(8):1843-6 [2317763.001]
  • [Cites] Mil Med. 2000 Dec;165(12):973-4 [11149072.001]
  • [Cites] Radiology. 1985 Mar;154(3):601-4 [2578678.001]
  • (PMID = 19014682.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2590613
  •  go-up   go-down


94. Mai KT, Belanger EC, Al-Maghrabi HM, Robertson S, Wang D, Margnean C: Primary prostatic central zone adenocarcinoma. Pathol Res Pract; 2008;204(4):251-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary prostatic central zone adenocarcinoma.
  • The central zone (CZ) of the prostate is embryologically, anatomically, and histologically distinct.
  • High-grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma (PAC) are encountered in the CZ, but have not been well studied.
  • The correlating positive biopsy cores were from the mid portion or from base of prostate and contained foci of HGPIN in 4/7 cases.
  • Preoperative diagnosis of CZ PAC can be suspected due to the histopathological features in the biopsy and is important to improve the free surgical resection rate.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Ductal / pathology. Prostate / pathology. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18178014.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


95. Knight D, Peterson AC, Rini BI, Harlin H, Gajewski TF, Stadler WM: The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer. Prostate; 2009 Feb 1;69(2):142-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer.
  • BACKGROUND: Increasing evidence suggests that prostate cancer is visible to the immune system and is potentially responsive to immunotherapeutic interventions.
  • Previous work has identified prostate-specific membrane antigen (PSMA) as a potential antigen for T-cell recognition, and specific PSMA epitopes presented by HLA-A2 have been described.
  • METHODS: HLA-A2(+) patients with castrate-resistant prostate cancer and normal organ function were considered.
  • CONCLUSIONS: Our results suggest that the PSMA peptide LLHETDSAV is poorly immunogenic in humans and that alternative prostate cancer antigens should be pursued.
  • [MeSH-major] Adenocarcinoma / immunology. Antigens, Surface / immunology. Glutamate Carboxypeptidase II / immunology. Peptide Fragments / immunology. Prostatic Neoplasms / immunology
  • [MeSH-minor] Cancer Vaccines / therapeutic use. Epitopes / immunology. HLA-A2 Antigen / immunology. Humans. Interferon-gamma / immunology. Interleukin-12 / genetics. Interleukin-12 / therapeutic use. Male. Neoplasm Metastasis / immunology. Patient Selection. Recombinant Proteins / therapeutic use. T-Lymphocytes / immunology

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18942640.001).
  • [ISSN] 1097-0045
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Surface; 0 / Cancer Vaccines; 0 / Epitopes; 0 / HLA-A2 Antigen; 0 / Peptide Fragments; 0 / Recombinant Proteins; 187348-17-0 / Interleukin-12; 82115-62-6 / Interferon-gamma; EC 3.4.17.21 / Glutamate Carboxypeptidase II; EC 3.4.17.21 / glutamate carboxypeptidase II, human
  •  go-up   go-down


96. Kesarwani P, Singh R, Mittal RD: Association of GSTM3 intron 6 variant with cigarette smoking, tobacco chewing and alcohol as modifier factors for prostate cancer risk. Arch Toxicol; 2009 Apr;83(4):351-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of GSTM3 intron 6 variant with cigarette smoking, tobacco chewing and alcohol as modifier factors for prostate cancer risk.
  • The present study aimed to explore the association of GSTM3 intron 6 polymorphism with susceptibility to prostate cancer (PCa), and to assess risks associated with cigarette smoking, tobacco chewing and alcohol consumption in PCa patients of North India.
  • Risk of developing prostate cancer associated with GSTM3 AB + BB was 2.5-fold (OR = 2.51, P = 0.028) as compared to AA genotype.
  • [MeSH-major] Adenocarcinoma / genetics. Alcohol Drinking / genetics. Genetic Predisposition to Disease. Glutathione Transferase / genetics. Polymorphism, Restriction Fragment Length. Prostatic Neoplasms / genetics. Smoking / genetics


97. Heijmink SW, Scheenen TW, Fütterer JJ, Klomp DW, Heesakkers RA, Hulsbergen-van de Kaa CA, van Lin EN, Heerschap A, Barentsz JO: Prostate and lymph node proton magnetic resonance (MR) spectroscopic imaging with external array coils at 3 T to detect recurrent prostate cancer after radiation therapy. Invest Radiol; 2007 Jun;42(6):420-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate and lymph node proton magnetic resonance (MR) spectroscopic imaging with external array coils at 3 T to detect recurrent prostate cancer after radiation therapy.
  • In a patient suspected of having recurrent prostate cancer after radiation therapy, we demonstrate the feasibility of noninvasive proton magnetic resonance spectroscopic (1H-MRS) imaging of the prostate and a lymph node at 3 T using a matrix of external surface coils.
  • With 1H-MRS imaging, high choline with low citrate signal was observed in the prostate, and in the lymph node a signal of choline-containing compounds was identified.
  • Subsequent histopathological analysis of systematic transrectal ultrasound-guided prostate biopsy and computed tomography-guided biopsy of the lymph node confirmed the presence of prostate cancer in both.
  • [MeSH-major] Adenocarcinoma / pathology. Magnetic Resonance Spectroscopy / methods. Prostatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17507814.001).
  • [ISSN] 0020-9996
  • [Journal-full-title] Investigative radiology
  • [ISO-abbreviation] Invest Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] N91BDP6H0X / Choline
  •  go-up   go-down


98. Goya M, Ishii G, Miyamoto S, Hasebe T, Nagai K, Yonou H, Hatano T, Ogawa Y, Ochiai A: Prostate-specific antigen induces apoptosis of osteoclast precursors: potential role in osteoblastic bone metastases of prostate cancer. Prostate; 2006 Nov 1;66(15):1573-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate-specific antigen induces apoptosis of osteoclast precursors: potential role in osteoblastic bone metastases of prostate cancer.
  • BACKGROUND: Prostate cancer is frequently associated with bone metastases with marked osteoblastic changes and low osteoclastic activity but its mechanism is not well understood.
  • We previously reported that prostate-specific antigen (PSA) stimulated the proliferation and the activation of osteoblasts.
  • METHODS: Two human prostate cancer cell lines and PSA were directly injected into human adult bone (HAB) implanted into NOD/SCID mice, followed by morphological analysis.
  • [MeSH-major] Adenocarcinoma / secondary. Apoptosis / drug effects. Bone Neoplasms / secondary. Osteoblasts / pathology. Osteoclasts / pathology. Prostate-Specific Antigen / pharmacology. Prostatic Neoplasms / pathology


99. Hirano D, Minei S, Kishimoto Y, Yamaguchi K, Hachiya T, Yoshida T, Yoshikawa T, Endoh M, Yamanaka Y, Yamamoto T, Satoh Y, Ishida H, Okada K, Takimoto Y: Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy. Urol Int; 2005;75(1):43-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy.
  • INTRODUCTION: Estramustine phosphate (EMP) in combination with other cytotoxic agents has been widely used in clinical trials as an anti-tumor agent for the treatment of hormone-refractory prostate cancer (HRPC).
  • However, few prospective studies have considered the efficacy of EMP monotherapy for HRPC patients following androgen-deprivation therapy (ADT), given the availability of methods to measure prostate-specific antigen (PSA) levels in the serum.
  • METHODS: After a diagnosis of anti-androgen withdrawal syndrome had been excluded, 34 patients with HRPC who showed an elevated serum PSA level in 3 or more sequential tests following ADT were treated orally with 560 mg/day of EMP.
  • With a median follow-up time of 20.0 (range 3.2-45.6) months, the cancer-specific survival rate at 2 years was 83% in the PSA responders and 44% in the non-responders.
  • The PSA response was correlated with cancer-specific survival (p = 0.029).
  • [MeSH-major] Adenocarcinoma / drug therapy. Androgens / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Estramustine / therapeutic use. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Disease Progression. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Prostate-Specific Antigen / blood. Treatment Outcome

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2005 S. Karger AG, Basel
  • (PMID = 16037707.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Androgens; 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 35LT29625A / Estramustine; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


100. Veltri RW, Miller MC, Isharwal S, Marlow C, Makarov DV, Partin AW: Prediction of prostate-specific antigen recurrence in men with long-term follow-up postprostatectomy using quantitative nuclear morphometry. Cancer Epidemiol Biomarkers Prev; 2008 Jan;17(1):102-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prediction of prostate-specific antigen recurrence in men with long-term follow-up postprostatectomy using quantitative nuclear morphometry.
  • We evaluated the use of a patient-specific quantitative nuclear grade (QNG) alone and in combination with routine pathologic features to predict biochemical [prostate-specific antigen (PSA)] recurrence-free survival in patients with prostate cancer.
  • METHODS: The National Cancer Institute Cooperative Prostate Cancer Tissue Resource (NCI-CPCTR) tissue microarray was prepared from radical prostatectomy cases treated in 1991 to 1992.
  • [MeSH-major] Adenocarcinoma / pathology. DNA, Neoplasm / analysis. Neoplasm Recurrence, Local / diagnosis. Prostate-Specific Antigen / blood. Prostatectomy. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18199716.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down






Advertisement